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Chapter 7 
MENSTRUAL DISORDERS IN 
ADOLESCENT FEMALES 
Donald E Greydanus*, MD, Hatim A Omar, MD, 
Artemis K Tsitsika, MD, PhD and Dilip R Patel, MD 
Michigan State University College of Human Medicine, 
MSU/Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, 
United States of America, Adolescent Medicine and Young Parent 
Programs, Kentucky Clinic, University of Kentucky, Lexington, 
Kentucky, United States of America and Adolescent Health Unit, Second 
Department of Pediatrics, University of Athens-Greece and« P & A 
Kyriakou » Children's Hospital, Athens, Greece 
Onset of menstruation (i.e., menarche) is a determining event 
of the adolescent female signifying the progress of puberty, which in 
the majority of cases is visibly initiated with thelarche (onset of 
breast development or breast buds). Menarche usually occurs during 
the earlier time of the second decade of life and ends with 
menopause,  typically in  the  5th   decade  of  life.   The  adolescent  can 
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present with a wide variety of menstrual dilemmas and disorders 
which will be discussed in this chapter. 
INTRODUCTION 
The onset of menstruation (i.e., menarche) is a seminal event of the 
adolescent female signifying the progress of puberty, which in the 
majority of cases is visibly initiated with thelarche (onset of breast 
development or breast buds). Menarche usually occurs during the earlier 
time of the second decade of life and ends with menopause, typically in the 
5th decade of life(1). The adolescent can present with a wide variety of 
menstrual dilemmas and disorders. After an introduction which 
includes a synopsis of menstrual physiology, many of these menstrual 
conditions arc considered in this discussion, including dysfunctional 
uterine bleeding (DUB), amenorrhea (primary and secondary) and 
dysmenorrhea (primary and secondary) (1,2).  
PHYSIOLOGY OF MENSTRUATION 
Puberty is the period involving the development of secondary sexual 
characteristics and the attainment of sexual reproduction capacity (3). 
The transition of puberty occurs usually between 10 and 16+ years of age 
and is impacted by several hormones which affect the cellular and 
glandular components of the reproductive system, leading to the 
anatomical changes of puberty.  Thelarche occurs  on average between 10 
to 1 0.5 years of age with a range of  8 to 13 years in Caucasian females 
and earlier in African-American females (4,5). Menarche occurs on 
average at 12.0 years of age in African-American females and 12.6 for 
Caucasian females; a wide range is noted from 9 to 16 years (4,5). The 
development of regular ovulatory menstrual cycles may take 1 to 5 years 
after menarche as the hypothalamic-pituitary-ovarian (HPO) axis 
continues to mature (1,6). Table 1 provides definitions for important 
menstrual disorders. 
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Table 1. Menstrual disorders definitions* 
1. Normal adult menstrual cycle:
a. Mean interval of 28 days (±7 days)
b. Duration of menses of 4 days (±2-3 days)
c . Median blood loss is about 30 ml per month ( with the upper
limit of normal defined as 60-80 ml per month) 
• Reprinted, with permission from: Greydanus DE. Breast and gynecological
disorders. In: Hofmann AD, Greydanus DE, eds. Adolescent medicine, 3rd
ed. Stamford, CT: Appleton Lauge, 1997:547. 
Physical changes in breast and pubic hair development as well as in 
somatic growth present clear evidence of the pubertal process. Various 
hormonal changes precede these physical changes by years and involve 
the hypothalamic-pituitary-gonadal axis that has a feedback loop with 
both inhibitory (negative) and stimulant (positive) processes. Several 
hormones are secreted by the hypothalamus, as noted in table 2. Many of 
these hormones are short acting and are released during late childhood at 
night, with increasing pulsatile frequency into the portal circulation of 
the hypothalamus.  
GnRH pulsatile secretion from the arcuate nuclei in the 
hypothalamus eventually leads the anterior pituitary to release the 
2. Amenorrhea : Absence of menses; can be Primary or Secondary
(absence of three consequent menstrual cycles, after regular periods
have been established)
3. Oligomenorhea: Infrequent. irregular bleeding at >45-day intervals
4. Menorrhagia: Prolonged (>7 days) or excessive (>80 ml) uterine 
bleeding occurring at regular intervals
5. Metrorrhagia: Uterine bleeding occurring at irregular but frequent
intervals, the amount being variable
6. Menometrorrhagia: Prolonged uterine bleeding occurring at 
irregular intervals
7. Hypermenorrhea: Synonymous with meno1rhagia 
8. Polymenorrhea: Uterine bleeding occurring at regular intervals of
<21 days
9. Dysfunctional uterine bleeding: abnormal (different from that 
patient's normal) uterine bleeding that is unrelated to any anatomic 
lesion
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gonadotropins, follicular-stimulating hormone (FSH) and luteinizing 
hormone (LH). leading to stimulation of the sex (gonadal) steroids, 
estrogen, and progesterone. FSH stimulates estrogen production and LH 
stimulates androgen production, with resultant development of breasts, 
pubic hair, and testicular enlargement in males. A negative or inhibitory 
influence on the hypothalamus i  induced by estrogen and progesterone. 
The menstrual cycle is generally divided into three phases (see figure l): 
follicular phase (the first phase), ovulation (the second phase), and the 
luteal phase (third or final phase). The fertile window is noted between the 
first and third phases. The hypothalamus serves as a generator of puberty, 
while GnRH seves as a regulator controlling menstrual cycling. 
Table 2. Hormones secreted by the hypothalamus 
Gonadotropin releasing hormone (GnRH) 
Thyrotropin releasing hormone (TRH), 
Growth hormone releasing hormone (GHRH), 
Corticotropin releasing hormone (CRH) 
Somatostatin  
Dopamine 
FOLLICULAR PHASE 
This initial phase of the menstrual cycle involves ovarian follicle 
development and endometrial growth stimulation over an  approximate 14 
day time period. The main hormone in this phase is estrogen and its 
production depends on various hormones, including GnRH, FSH, LH., and 
inhibin. GnRH moves through the portal plexus of the hypothalamus to the 
anterior pituitary gland to stimulate the production of FSH and LH. The 
production rate of these pituitary gonadotropins depends on the 
secretion of estrogen and progesterone from the ovaries, as well as 
GnRH from the hypothalamus. Hypothalamic, pituitary, or ovarian 
dysfunction can all lead to menstrual disorders (7,8).  
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Ovarian cycle 
Figure 1. The normal menstrual cycle. 
OVULATION
Ovarian follicles remain in cycles of growth and atrophy during the 
menstrual life of the female. The rise of FSH a few days prior to 
menstruation stimulates FSH receptors in ovarian follicles with resultant 
development of various follicles (typically 3 to 11), and the follicle with 
the highest FSH sensitivity is destined to be the dominant follicle of that 
specific cycle (9,10). Estrogen is released from the developing follicle, 
while the glycoprotein, FSH, affects the follicular granulosa cells for 
ongoing growth as well as increase in LH receptors. The glycoprotein, 
LH, affects the theca cells of the maturing ovarian follicles with resultant 
androgen production. Androgen to estrogen conversion is enhanced by 
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FSH because of increased follicular aromatase activity and further follicle 
maturation.  
There is a negative feedback loop in which estrogen from the 
dominant ovarian follicle reduces pituitary FSH production while a 
positive feedback loop allows increased LH secretion. Inbibins A and B are 
hormones that are secreted by the ovarian follicle with resultant pituitary 
feedback to reduce FSH production, while activins raise follicular 
sensitivity to LH (11). The result is continued maturation of the dominant 
follicle over that of the other maturing follicles. Levels of estrogen rise until 
approximately the first 14 days (day 13 or 14) of tile menstrual cycle, when 
a critical estrogen level is reached that induces a major increase in LH (LH 
peak ot surge) and resultant ovulation. 
The ovulatory part of the menstrual cycle usually occurs over a 1 to 
2 day time period and initiates the final menstrual phase, the luteal phase. 
The LH surge that occurs in the middle of the normal menstrual cycle 
leads to ovulation and the release of the oocyte from the dominant ovarian 
follicle and also the resumption of meiosis of the oocyte. Gradual 
progesterone increase is noted during the 24 hours prior to and after 
ovulation and if pregnancy does not occur, the follicle becomes the 
corpus luteum that mainly produces progesterone in a sustained fashion. 
LUTEAL PHASE 
The surge of LH production occurs in the middle of the menstrual cycle, 
resulting in ovulation that lasts 1-2 days and creates a window of fertility of 
approximately 6 days; the length of the fertile window depends on various 
factors, including gynecological age and actual menstrual length. The 
dominant ovarian follicle is released and becomes the corpus luteum, 
producing persistent secretion of progesterone over a timeline of 
approximately 12 days, unless normal pregnancy occurs with resultant 
human chorionic gonadotropin (hCG, HCG) production. Ovulation-
induced progesterone secretion leads to a period of altered glandular 
secretion and stromal changes, preparing the endometrium for possible 
implantation of a blastocyte. The increased progeste-rone reduces 
pituitary  FSH  and  LH  secretion  via  a  negative  feedback  loop  and  also 
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reduces  GnRH pulsatile secretion that results in  less gonadotropin 
secretion (i.e., FSH and LH) (12). 
The rise in estrogen in the early follicular phase leads to estrogen 
binding with endometrial receptors, growth factor stimulation with 
resultant blood vessel stabilization and growth of endometrial tissue, 
including spirol arterioles, stroma, and glands. Post-ovulatory rise in 
progesterone leads to transformation of the endometrium from a 
proliferative to a secretory state, with glands that are more and more 
tortuous, with production of secretions rich with glycogen and preparing 
for implantation. The endometrium becomes edematous and very 
vascular. 
If pregnancy does not occur, the natural life of the corpus luteum 
ends on the fourteenth day of the luteal phase and as it involutes, there is 
a dramatic reduction in progesterone that induces menstruation. As the 
progesterone production is reduced, pulsatile GnRH production 
rejuvenates and a new menstrual cycle is reborn with the potential of 
another pregnancy. Menstruation (menstrual period; menses) is the term 
which refers to the bleeding event which results when the endometrium 
desquamates, due to the withdrawal of estrogen and progesterone. 
  Initial effect of hormone withdrawal is reduction of half of the 
endometrial mass tissue because of fluid  absorption  and  vasoconstriction 
of  spiral   arterioles,   mainly   under  the  influence  of  prostaglandin   F2α 
(PGF2α) and  endothelin-1 with resultant reduction in blood now. The  
periodic vasoconstriction (over 24 hours) and relaxation of endometrial 
arterioles  results in endometrial ischemia that helps to induce 
local release of cytokines (as tumor necrosis factor alfa) and other signaling 
molecules (13). There is also loss of hyaluronic acid and water from the 
regressing endometrium, as well as major extracellular matrix destruction 
noted just before and during menses (14). Also noted is activation of 
proinflammatory cytokines and matrix metalloproteinases (MMPs: 
MMP-I, MMP-3, MMP-9) in the endometrium that contribute to tissue 
breakdown independent of the vasoconstriction physiology (11,1 5, 16). 
Finn (17) has contended that the process of menstruation is an 
inflammatory one with edema of tissues, migration of leukocytes, and 
decidual cells suggesting granulation tissue fibroblasts. Indeed, there are 
various inflammatory cells present, including macrophages,  granulated 
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lymphocytes, and polymorphonuclear leukocytes that contribute to 
vascular permeability and breakdown of endometrial tissue via release of 
various regulatory molecules. Interleukin-8 is a cytokine that leads to the 
release of various chemicals, such as tryptase and chymase, with 
resultant influence on leukocyte migration to the endometrium that help 
induce endometrial breakdown. 
Essential to normal menstruation is normal blood coagulation with 
generation of thrombin-induced fibrin that is stimulated by tissue factor 
in the endometrium via the extrinsic pathway. Tissue factor rises in 
decidual cells of the endometrium because of progesterone and tissue 
factor foils with the fall of progesterone. It is noted that fibrin-platelet plugs 
are found in superficial blood vessels and not in the surrounding          
tissue because of endometrial fibrioolytic pathways. A balance is 
necessary to be achieved between the coagulation factors' production 
that controls bleeding and the process of fibrinolysis that stops clot 
organization and intrauterine adhesion. Indeed, the coagulation process is 
mainly one of hemostasis in the secretory menstrual phase and a 
fib1inolytic process in overt menses. As apoptosis and necrosis continues, 
endometrial tissue shrinks and much of this layer breaks down into 
fragments with much blood and fluid that are expelled into the uterine 
cavity and lost.  
Eventually the blood Joss stops, and repair of tissue occurs because     
of increasing estrogen with local growth factors release and sustained 
vasoconstriction. VEGF (vascular endothelial growth factor) is an 
angiogenic chemical that is induced by hypoxia and is vital to the overall 
endometrial repair process (18). The process of endometrial angiogenesis 
is a complex one and related to influence of VEGF and the fibroblast 
growth factors that are produced, in part, by the migration of leukocytes to 
the endometrium (19-21). 
After ovulation, the corpus luteum leads to progesterone production 
that changes the endometrium to a secretory state, with a decidualized 
stroma that has increased edema and vascularity along with glands that are 
tortuous and abundant in glycogen. As the corpus luteum dies, both 
estrogen and progesterone rapidly decrease, with resultant endometrial 
atrophy and loss of approximately 50% endometrial mass in 24 hours. 
Vascular vasoconstriction leads to the end of menstruation. Disruption in 
this process of angiogenesis  leads to menstrual  dysfunction  and  abnormal 
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bleeding. Failure to develop a fully mature secretory endometrium 
characterizes a luteal phase defect (22,23).  
DYSFUNCTIONAL UTERINE BLEEDING 
Dysfunctional uterine bleeding (DUB), one of the most urgent adolescent 
gynecological conditions, refers to prolonged, excessive, or unpatterned 
uterine endometrial bleeding not caused by uterine anatomical conditions 
(1,24). Causes of abnormal menstrual bleeding are noted in table 3 and 
include coagulation disorders, infections, trauma, pregnancy 
complications, systemic conditions, local lesions, and various 
reproductive tract pathology; these etiologies need to be eliminated 
before using the diagnosis of DUB (1,6,25). Premature menarche has 
been noted on occasion in girls in which one or more episodes of vaginal 
bleeding occurs without evidence of pubertal changes; it is usually 
idiopathic but may be associated with hypothyroidism or other causes 
(26,27). 
Approximately 15% of adult women present with DUB and this 
number is much higher in the adolescent female population. One 
questionnaire-based study of 1,410 high school females with a mean age 
of 16.7 years revealed that 37% had a history of heavy menstruation,    
38% had a family history positive for heavy menses, and 22% of these 
adolescent females had been treated with hormonal therapy for their 
menstrual condition (28). Complications in cases of coagulation   
disorders include anemia, spontaneous bleeding into joints or muscles, 
increased bleeding after surgery, and increased absence from school    
and/or work. 
A major cause of DUB in adolescents is anovulatory irregular 
menstruation, typically due to lack of the positive feedback effect of 
estradiol and absence of ovulation at menarche and for 1-5 years after 
menarche (29). For example, research notes that anovulation occurs in 
55% to 82% of menstrual cycles in adolescents at menarche and for 2  
years after menarche while anovulation occurs in 30% to 45% of menses 
from years 2 to 4 after menarche, and no more than 20% of menses from 
years 4 to 5 (30). 
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Levels of the glycoproteins LH and FSH, as well as the hormones 
estrogen and progesterone are below that of normal adult female levels 
during the first year after menarche. While estradiol levels increase to 
normal adult levels by year two post-menarche, progesterone levels 
remain low for up to 5 years after menarche, and LH/FSH are at adult 
levels by year 5. LH secretion is mainly nocturnal and episodic before 
puberty and as puberty develops. LH secretion increases and normal 
timing of LH pulses are necessary for developing normal ovulatory    
cycles.  
Increased estrogen leads to less GnRH with reductions in FSH and LH 
and resultant less stimulation of estrogen that can lead to     
vasoconstriction and atrophy of thickened endometrium and resultant 
heavy, prolonged menstrual bleeding. Estrogen that is unopposed by 
progesterone leads to growth of the endometrium that eventually cannot 
be supported by its blood supply and results in partial endometrial 
breakdown with irregular shedding and bleeding. Failure of ovulation   
and resultant unopposed estrogen leads to decreased vascular tone of 
endometrial blood vessels, with inhibition of vasopressin release and 
resultant vasodilatation and increased menstrual bleeding (31). 
Unopposed estrogen also induces VEGF production with resultant 
angiogenesis (31). The endometrium that is not exposed to progesterone 
produces less prostanglandin (PG) and a greater ratio of PGE than PGF. 
Excessive blood loss may also be due co increased development of 
endometrial nitric oxide (endochelium-derived relaxing factor) that is 
stimulated by unopposed estrogen (32). 
Table 3. Causes of abnormal menstrual bleeding in adolescents* 
(Exclude rectal, urethral. and  other perineal bleeding) 
Vaginal or uterine abnormalities 
Trauma (coitus, rape, abuse) 
Foreign body (IUD, tampon, etc) 
Infection 
Vaginitis (trichomonas, gonorrhea) 
Cervicitis
Endometrilis (tuberculosis) 
Pelvic inflammatory disease 
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Sexually transmitted condylomata (HPV) of cervix or vagina 
Tumor 
Botryoid sarcoma 
Polyps (uterine, cervical)  
Ovarian cyst or tumor (mature teratoma, endometrioma) 
Leiomyomatosis 
Clear cell carcinoma of cervix or vagina (DBS) 
Other ovarian malignancy and metastatic malignancy 
Endometriosis 
Congenital malformations of utems 
Complications of pregnancy 
Threatened or spontaneous abortion 
Ectopic pregnancy 
Molar pregnancy 
Induced abortion 
Coagulopathy 
Generalized 
    Thrombocytopenia (idiopathic thrombocytopenic purpura; leukemia; 
lymphoma; aplastic anemia, hypersplenism) 
Platelet dysfunction (Glanzmann's disease) 
Clotting disorders (hemophilia; von Willebrand's disease; other 
coagulation factor deficiencies) 
Uterine production of menstrual anticoagulant, 
Dysfunctional uterine bleeding 
Normal variation 
Midcycle ovulatory bleeding 
Early postmenarcheal anovulation 
Early postmenarcheal estrogen irregularities 
Chronic anovulation 
Exogenous steroids 
Oral contraception 
Midcycle breakthrough bleeding 
             Relative luteal progesterone deficiency 
Progestogens (oral agents; Norplant; Depo-Provera) 
Continuous estrogens 
Other drugs 
Danazol 
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Spironolactone 
Anticoagulants 
Platelet inhibitors 
Chemotherapy drugs 
Natural hor.01ones from plant extracts (DHEA, Dong Quai, 
Yam Extract) 
Systemic diseases 
Hyperthyroidism or  hypothyroidism 
Adrenal insufficiency 
Cushing's syndrome 
Diabetes mellitus 
Chronic liver disease 
Crohn's disease; ulcerative colitis 
Chronic renal disease 
Systemic lupus erythema1osus 
Ovarian failure 
Hyperprolactinemia 
Androgen excess 
Exogenous androgens, PCOS, congenital adrenal 
hyperplasias 
Androgen producing ovarian or adrenal tumor 
Estrogen excess 
Granulosa-theca cell tumor of the ovary 
Other tumors 
Hypothalamic 
Emotional stress 
Physical stress, especially exercise 
Ovulatory 
Short luteal phase 
Prolonged luteal phase (Halban's disease)
        Luteal progesterone insufficiency  
Abbreviations: lUD = Intrau1erine device; HPV = human papillomavirus; 
DES: diethylstilbestrol •
* Reprinted, with permission from: Greydanus DE. Breast and gynecological
disorders. In: Hofmann AD, Greydanus DB, eds. Adolescent medicine, 3rd  
ed. Stamford, CT: Appleton Lange, 1997:547. 
    Though anovulation is the main stimulant to DUB, abnormal 
menstrual bleeding   can  also   occur   in   ovulatory   states,  as,  for example,  in 
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the Halban syndrome or prolonged progesterone in which a persistent 
corpus luteum cyst leads to 6 to 8 weeks of amenorrhea, followed by 
irregular menses (22,23). 
COAGULATION AND DUB 
An important aspect of normal blood clotting in controlling menstrual 
bleeding is the generation of thrombin-induced fibrin, as induced in the 
endometrium by tissue factors utilizing the extrinsic pathway of 
coagulation (6). Fibrin-platelet plugs develop in superficial blood vessels 
due to endometrial fibrinolytic pathways and there is a balance between 
coagulation factors that control bleeding and fibrinolysis to prevent 
organization of clots and intrauterine adhesion. In menstruation, there is 
a shift to fibrinolytic mechanisms with endometrial breakdown and 
shedding of uterine material that is expelled with variable loss of tissue 
and blood. 
Eventually, prolonged vasoconstriction occurs along with local 
growth factors that are released and increase in estrodiol production that 
stops blood loss. Repair of epitheliurn develops with the production of 
angiogenic factors as VEGF (vascular endothelial growth factor), that is 
stimulated by hypoxia (6). Angiogenesis in the endometrium involves the 
formation of new vasculature from pre-existing vessels because of the 
effects of VEGF and FGF (fibroblast growth factor). Migratory 
leukocytes are an important part of this cyclical angiogenesis, as noted 
earlier.  
CONGENITAL COAGULATION DISORDERS 
Severe dysfunctional uterine bleeding may be the first indication of an 
underlying bleeding disorder (see table 4). Studies note that 19% to 28% 
of adolescents who are hospitalized due to acute menstrual bleeding have 
a coagulation disorder (33,34 ). Approximately 80%-85% of inherited 
bleeding disorders are Hemophilia A (F (factor] VIII deficiency), Von 
Willebrand's Disease (vWD) and Hemophilia B (F IX deficiency) 
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(1,9,35,36). Approximately 15% are congenital bleeding disorders that 
include deficiencies of fibrinogen, prothrombin, and factors V, VII, X,   
XI, XIll and combined V + VII (1,36-38). Approximately 20-30% of those 
with menorrhagia have platelet dysfunction while 13%-17% have             
von Willebrand's disease (25). 
Von Willebrand's Disease (vWD) 
VWD is an autosomally inherited condition affecting 1% to 3% of the 
population and caused by a gene on chromosome 12. VWD is either a 
quantitative or qualitative defect of the production of vW factor; this           
factor is a protein needed for normal platelet adhesion at injured 
endothelium and for preservation of circulatory Factor VIII (36). Clinical 
findings and laboratory evaluation will identify vVD including 
Quantitative types 1 or 3 and Qualitative 2, with its various subtypes: 2a, 
2b, 2m, and 2n. 
Table 4. Coagulation disorders 
Hemophilia A (F (factor] VTII deficiency) 
Hemophilia B (FIX deficiency) 
Von Willebrand's Disease (vWD) 
Platelet function defect 
Thrombocytopenia 
Factor deficieocie : F V,  XI, XIII, VII, II 
Fibrinogen deficiency 
Others 
The mildest vWD type is 1 with only moderate vW factor reduction 
and this involves 70% to 80% of this disorder. Both types 1 and 2 are 
often not identified until adolescence or adulthood, in which suspicion 
arises after bleeding is noted with severe trauma or surgery. Suspicion 
may also develop because the adolescent female presents with 
menorrhagia as her first clinical evidence of vWD. The first report of 
vWD was by Erik von Willebrand in 1926 in which 16 of 23 affected 
family members were female and the index case was  a  young  adolescent 
Menstntal Disorders in Adolescent Females 331 
female, who died at age 13 years from uncontrolled bleeding during her 
4th menstrual period; she probably was a type 3 vWD (39). A number of 
adult females with vWD eventually resort co hysterectomy to stop the 
severe menorrhagia.  
Hemophilia 
Hemophilia occurs in I in 5,000 males and is caused by genes at the long 
arm tip of the X chromosome; Hemophilia A is deficiency of Factor VIII 
while Hemophila B is deficiency of Factor IX (36). Normal plasma 
levels of F VIII and F IX   are 50% to 150%. Hemophilia can be divided 
into three levels of severity: mild, moderate, and severe. Mild hemophilia 
is defined by a factor level over 5% and represents 20% in contrast to 
moderate hemophilia with levels of 1% to 5% (15% of cases) and severe 
with factor levels under 1 % (65% of cases). Mild hemophilia may not be 
diagnosed until adolescence. 
DUB AND COAGULATION DISORDERS
Table 5 lists laboratory tests useful for screening adolescent females with 
severe menorrhagia in which a coagulation disorder must be considered 
as part of the differential diagnosis (1,9,36,40). Coagulation disorder 
prevalence in those with severe menorrhagia varies in published studies, 
depending on the population studied. In one study of 1,410 high school 
females, though 37% noted heavy menses, only 8 had an actual bleeding 
disorder diagnosis (28). The classic paper by Claessens and Cowel in 
1981 ( 41) noted that 19% of those who were hospitalized because of 
severe menorrhagia had a coagulation disorder, while 28% had a 
coagulation disorder if there was severe anemia, and 45% if severe 
bleeding with hospitalization occurred with the first menstrual period 
(menarche) (versus 65% in Kadir's 1998 study) (42). In Falcone's 1994 
study 3% of adolescent females with DUB were diagnosed with a 
coagulation disorder, 41% received blood transfusions, 93% improved 
with hormonal treatment, 8% were managed with a D and C. Also, 34% 
received a D and C (dilation and curettage) (43). 
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The mildest vWD type is 1 with only moderate vW factor reduction 
and this involves 70% to 80% of this disorder. Both types 1 and 2 are 
often not identified until adolescence or adulthood, in which suspicion 
arises after bleeding is noted with severe trauma or surgery. Suspicion 
may also develop because the adolescent female presents with 
menorrhagia as her first clinical evidence of v\VD. The first report of 
vWD was by Erik von Willebrand in 1926 in which 16 of 23 affected 
family members were female and the index case was a young adolescent 
female, who died at age J 3 years from uncontrolled bleeding during her 
4th menstrual period; she probably was a type 3 vWD (39). A number of 
adult females with vWD eventually resort to hysterectomy to stop the 
severe menorrhagia.  
Table 5. Laboratory screening for severe menorrhagia 
Initial Screening 
Complete blood count with differential; hCG testing 
Platelet function analysis (PFA) (Has replaced the old bleeding time 
test)  
Fibrinogen 
Bleeding Studies 
a. Prothrombin time (PT)
b. Activated partial thromboplastin time (aPTT)
Secondary Screening* 
von Willebrand's factor antigen 
Factor VITI activity 
Factor XI antigen 
Ristocetin C co-factor 
Platelet aggregation studies •
*  (severe or prolonged bleeding, menorrbagia with menarche, abnormal first 
             tests)  
Severe menstrual bleeding was reported in one study of 102 females 
with vWD (versus 88 controls) in 74% of those with vWD versus 6% of 
the controls (44). TI1ose with vWD have a higher incidence of 
menon-hagia, severe bleeding postpartum, migraine headaches, and 
arthritis. Such a negative impact of vWD is noted in other studies. For 
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example, one report studied type I vWD patients using a patient survey 
of 99 patients (81 still menstruating) with mild disease versus 15O 
controls. In this study, those with vWD had a statistically increased 
history of anemia, number of tampons or towels used in menses, number 
with stained clothes due to menses, and birth-related bleeding that 
required blood transfusions (39). In the group with vWD, there was a 
reduced quality of life due to increased bleeding problems, only 50% 
reported hormonal management that was effective, 17% reported that a D 
and C was needed, and 13% had hysterectomy (39). 
In another study of 116 female with inherited bleeding disorders 
(IBD) versus 69 controls. 66 had vWD (74% with menorrhagia), 30 were 
carriers of hemophilia (57% with menorrhagia) and 20 had Factor XI 
deficiency (59% with menorrhagia); 29% of the controls who did not 
have IBD had menorrhagia (45,46). There was no association between 
the blood loss degree (as measured by the Pictoral Blood Assessment 
Chart) and disease severity in hemophilia or Factor XI deficiency. The 
degree of blood Joss could not be predicted based on the vW factor 
activity (vWF:Ac) (45,46). 
The duration of the menstrual period increases significantly in 
females with IBD, in contrast to those without IBD; there is an increase 
in menstrual flooding in those with IBD, but no difference in clot passage 
is reported. In those with IBD, 47% had seen their clinician because of 
the excessive menstrual bleeding, 36% received hormonal therapy due to 
menorrhagia and 27% received surgery (such as D and C or 
hysterectomy) (45). Also reported was that the use of the PBAC (Pictoral 
Blood Assessment Chart) is not reliable for assessing blood loss (45). 
One study looked at the the quality of life (QOL) in 99 with IBD in 
contrast to 69 controls that utilized a questionnaire asking about daily 
activities, general health, dysmenorrhea, and QOL during menstruation 
(42). In this study, there were 57 with vWD, 17 were Hemophilia 
A carriers. seven were Hemophilia B carriers, and 18 had Factor XI 
deficiency. The QOL was statistically lower if menorrhagia was present     
in those with IBD, if menses lasted eight or more days, and if there was 
menstrual flooding or passage of clots (see table 6) (42). 
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Table 6. Quality of life for 99 patients with inherited bleeding 
disorders (42) 
39% had cut down on time at work and other activity due to menses 
47% felt they accomplished less during menses than they would like 
38% felt they were limited in work 
40% needed extra effo1t in work 
51 % had moderate, severe or very severe dysmenorrhea 
DUB PROGNOSIS
DUB in adolescent females usually results from anovulatory 
mcostmation because of immaturity of the HPO axis (1,47-50). Most 
adolescents develop regular ovulatory menses between one and five 
years after menarche leading to regular menstrual patterns. The classic 
Southam and Richart 1966 study (51) found that if normal menstruation 
does not develop within four years of menarche, normal menstrual 
function will probably not develop in adult life. Many of these adult 
females had reduced reproductive potential and high rates of endometrial 
cancer, as there seems to be an underlying disease process causing the 
chronic bleeding abnormality. 
DUB MANAGEMENT 
Figure 2 outlines an evaluation process for adolescents with DUB. The 
management is dependent on the underlying cause and also the degree of 
anemia that may or may not be present; hormonal management is 
provided if necessary to control the abnormal bleeding (7). Mild anemia 
is defined as a hematocrit between >33% and < 36% or a hemoglobin > 
11 g/dl but < 12g/dl. Moderate anemia is defined by a hematocrit 
between 27% and 33% or hemoglobin between 9 and 11 g/dl. Severe 
anemia refers to a condition with a hematocrit under 27% or a 
hemoglobin under 9 g/dl or rapidly dropping. Management of DUB in 
adolescent females due to anovulatory menstruation is now discussed. 
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Absence of anemia or mild anemia 
Reassurance and watchful waiting is usually recommended in situations 
of anovulatory DUB if the patient is not overly concerned and there is no 
or only mild anemia. A menstrual calendar can be kept by the youth to 
better follow her menstrual panerns. Iron supplementation can be 
prescribed for mild anemia, such as ferrous sulfate at 300 mg three times a 
day; side effects adding iron are noted in table 7 (1,6). Constipation 
from iron supplementation may be prevented by adding a stool softener 
and a low release form of iron may lower the overall side effects. A 30% to 
50% reduction may be seen if non-steroidal anti-inflammatory drugs 
(NSAIDs) are given at menses because of a direct endometrial effect on the 
balance of thromboxane A2 (potent vasoconstrictor) and 
prostaglandin I2 (vasodilator). Thromboxane is a member of family of 
lipids called Eicosanoids that are produced in platelets (see table 8).  
Table 7. Adverse effects of iron supplementation 
Black stools 
Constipation (add stool softener to prevent) 
Diarrhea 
Nausea and emesis 
Worsenjng ulcers/colitis 
Table 8. Thromboxane production 
l) Arachidonjc Acid  →  Endoperoxides
2) Endoperoxides → Toromboxane A2 → Thromboxane Bz(Platelets)
3) Endoperoxides → Prostacyclin (PGI2)
4) Vasoconstrictor
5) Facilitates platelet. clumping 
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Used and adapted with permission from: Joffe A, Blythe  MJ.  Handbook of    
  adolescent medicine. Adolesc Med 2003; 14(2):294, figure 1; Greenfield TP, 
 Blythe MJ. Menstrual disorders in adolescents" In: Greydanus DE, Patel 
DR, Prall HD, eds, Essential adolescent medicine. New York, McGraw-Hill, 
2006:602. 
Figure 2. Evaluation of dysfunctional uterine bleeding in adolescent patients 
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Oral or 1ransdermal con1racep1ion (pills or patch) can also be an 
option m improve the DUB (especially if the adolescent is sexually 
active and it prevents unwanted pregnancy at the same time) (52-54). 
Instead of using oral contraceptives, some clinicians prescribe oral 
equine estrogen (2.5 mg for 21-25 days); 10 mg medroxyprogesterone 
acetate is then added over the last seven days of the cycle. An alternative 
is to use oral progesterone for the last 10 days of the menstrual cycle in 
order to preve1Jt the effects of unopposed estrogen and allow endometrial 
stabilization; a regular sloughing of the endometrium then occurs as 
progesterone is withdrawn (55). Adverse effects of cyclic oral progestin 
therapy include bloating, increased acne, hyperphagia with weight gain, 
and ineffective contraception. Alternatives used by some include a 
natural progestin or progesterone developed from wild yams or a finely 
ground or miconized form (Prometrium) used to avoid or reduce side 
effects, though there is no underlying research for their use (1). 
Dcpo-medroxy-progesterone acetate (DMPA; Depo-Provera) is not 
typically recommended for youth with DUB. because it may cause 
irregular bleeding that may later evolve into amenorrhea. As it is given in 
an intramuscular form, it should not be a first option in those with a 
coagulation disorder. However, DMPA may be provided in unique 
situations, such as a sexually active female with DUB and systemic lupus 
erythematosus who is on coumadin (56). Side effects of DMPA include 
weight gain, decreased bone mineral density, worsening of depression, 
protracted ovarian suppression, and hair loss.  
Moderate anemia 
DUB that induces moderate anemia may be controlled with an oral 
contraceptive pill with 30-35 mcg ethinyl estradiol (6,52,57). As noted 
previously, estrogen controls menstrual bleeding by binding to 
endometrial receptors, stimulating specific growth factors, and producing 
vasculature stabilization; estrogen stimulates the development of the 
glands, stroma, and spiral arterioles in the endometrium. The oral 
contraceptive (OCP) can be given in a dose of 2-4 pills a day, until the 
bleeding is stopped and then gradually tapered over 2 to 3 weeks (see 
table 9). The OCP can be stopped to allow withdrawal bleeding and then 
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added again as a once-a-day pattern for 3 to 6 months, in order to allow 
menstrual regulation and improvement of the anemia with iron 
supplementation. Increased estrogen may lead to nausea and emesis, thus 
necessitating the addition of an anti-emetic agent. 
Table 9. Schedule of oral contraceptives to control moderate to 
severe DUB 
1. Four times a day (with an anti-emetic) until the bleeding stops 
2. Three times a day for 4 days 
3. Twice a day for two to three weeks 
4. Allow a controlled withdrawal bleed 
5. Start the oral contraceptive and oral iron supplements at once a day 
for 3 to 6 months
Table 10 lists various oral progesterone-only patterns that are 
preferred by some clinicians; high doses may be necessary to induce 
cndomctrial atrophy and estrogen is added for several days to prevent 
unwanted endometrial break-through bleeding when progesterone-only 
medicat.ioos are used. As noted before, iron supplementation can be 
given for 3-6 months to correct depleted iron stores and a stool softener 
added to prevent constipation. 
Table 10. DUB control with progesterone-only agents 
A. Medroxy-progesterone acetate (MPA) 
1. 10 mg q 4 hours, then QID-4 days, TID-3 days, BID-14 day) 
2. high dose may be necessary: 40-80 mg per day or 100 mg Depo
IM/day 
B. Norethindrone acetate (Aygestin) 
1. 10 mg q 4 hours, then q6-8 hrs to 12 hours; taper as bleeding
decreases 
2. May stay on 5 mg q 12 h rs for months if necessary with ↑ if
necessary (as teen with aplastic anemia & low platelet count) 
3. 0.35 mg OD-BID for breakthrough bleeding 
C. Megestrol acetate (80 mg BID may be needed) 
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Severe anemia 
If severe anemia has developed as a result of DUB, emergency 
management may be necessary that includes provision of intravenous 
fluids and and blood products. Intravenous Premarin (conjugated equine 
estrogens) is given by some at a dose of 25 mg every 4 hours; Two doses 
are usually effective in 75% of patients and only 2-4 doses are usually 
needed, because of the hemostasis that results because of direct clotting 
effects with increased production of fibrinogen, Factor V and Factor IX 
activity and increased aggregation of platelets. Many clinicians will not 
use intravenous estrogen because it is not usually needed and because of 
the increased risk for thromboembolism that may be present when high 
doses of estrogen are used. An antiemetic agent must be added to offset 
the estrogen-induced nausea and emesis. A progesterone is added to 
allow a regulated menstrual bleeding. 
Instead of intravenous estrogen, many clinicians use oral 
contraceptives as outlined in table 9. Fortunately, such hormonal 
management is effective in controlling DUB in over 90% of such 
situations. If these measures are ineffective, other causes must be 
considered, such as coagulation disorders (9,43). Other medications can 
be added, such as Desmopressin acetate or antifibrinolylics, as 
considered in the next section.  
MANAGEMENT OF DUB DUE TO COAGULATION
DISORDERS 
Factor replacement therapy 
Table 11 lists methods of DUB management in patients with coagulation 
disorders (1,6,58,59). Control of menstrual bleeding is based on working 
with the delicate balance between thrombosis and bleeding. Hemostasis 
physiology involves three basic phases: vascular phase (blood vessel 
vasoconstriction), platelet phase (the primary hemostatic mechanism 
involving platelet plug formation), and the fibrin thrombus formation 
phase (60). The basis of management is factor replacement therapy 
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involving either factor VIII, Factor IX, or vW factor in which factor 
levels should be at 30% or more for minor bleeding and 100% for major 
bleeding as noted with surgery or intracranial hemorrhage. Recombinant 
Factor Concentrates are preferred if available; otherwise, pathogen-safe 
plasma-derived concentrates are used. Non-steroidal inflammatory drugs 
(NSAIDs) are not effective in reducing blood loss in those with inherited 
bleeding disorders. 
Table 11. Control of DUB in inherited coagulation disorders 
I. Factor replacement therapy 
2. Intranasal DDA VP 
3. Antifibrinolytics 
4. Oral contraceptives 
5. Levonorgestrel-releasing IUD (Mirena)
Intranasal DDA VP 
The treatment of choice is intranasal DDA VP (Desmopressin acetate; 1- 
deamino-8-D-arginine vasopressin) since it raises plasma concentrations 
of Factor VIII and vWF 2 to 6 fold by way of endogenous release of 
these factors. Intranasal DDA VP is best for those with Type 1 vWD with 
normal vWF available from storage sites; however. it can also help with 
menorrhagia in those with mild hemophilia and other von Willebrand 
types (36,38). 
Three forms of DDA VP are available: intranasal, subcutaneous (SC), 
and intravenous (IV). Concentrated intranasal DDA VP (Stimate) is made 
as a 1.5 mg/ml preparation with two-thirds the effect of the IV form and 
the formulation used to treat diabetes insipidus should not be used for 
patients with coagulation disorders and menorrhagia. A dose of 300 µg 
(2 metered doses) is used for those over 50 kg and the patient is then 
observed for 60 to 90 minutes after giving the medication. Side effects of 
intranasal DDAVP are listed in table 12 and include mild fluid restriction 
necessitating monitoring of the urinary output and daily weights for 
urinary retention. If the intravenous form of DDAVP is used, the dose is 
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0.3 g/kg given in 25-50 ml normal saline over 15-20 minutes; peak 
action occurs in 30 to 60 minutes. 
Table 12. Side effects of intranasal DDAVP 
1. Facial flushing (asymptomatic)
2. Thrombosis (rare) 
3. Hyponatremia (more common in children, if   given repeatedly, or too 
much fluid) 
4. Headaches
5. Nausea
6. Weakness 
Antifibrinolytics 
Antifibrinolytics (i.e., epsilon-aminocaproic acid (Amicar) or tranexamic 
acid) are also used as adjunctive management for menorrhagia in 
hemophilia, as well for mucosal bleeding (epistaxis, dental extraction, 
oral bleeding) (25,36,38). Antifibrinolytics improve coagulation by 
preventing clot degradation in areas high in fibrinolytic activity, 
inl1ibiting fibrinolysis, and by preventing change of plasminogen to 
plasmin. They can be taken along with DDAVP, factor replacement 
therapy, and coagulation Factor IX concentrates. Antifibrinolytics should 
not be taken immediately with prothrombin-complex concentrates 
(PCCs), because of increased risk for clot formation; however, they can 
be taken 4-6 hours after PCCs are stopped. Side effects of 
antifibrinolytics are noted in table 13. 
Table 13. Side effects of antifibrinolytics 
l. Nausea and emesis
2. Headaches
3. Abdominal pain 
4. Avoid with urinary tract bleeding due to potential for intrarenal clots
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Tranexamic acid (Cyklokapron) improves menorrhagia by 
significant lowering of plasminogen activator activity and plasmin activity 
in menstrual fluid. It  is used in Europe and given orally at a dose 
of 20-25 mg/kg q 6-8 hours orally (maximum: 1.5 grams) or at an 
intravenous dose of 10 mg/kg q 8 hours (Max: 1 gram); the IV form is used 
in the United States. Epsilon-aminocaproic acid (EACA; Amicar) is 
prescribed as oral medication (flavored syrup or tablets) at a dose of 50- 
100 mg/kg q 6 hrs (maximum is 24 grams per day). Gastrointestinal side 
effects can be increased at higher doses.  
Oral contraceptives 
Females with DUB and inherited bleeding conditions can also be treated 
with oral contraceptives (OCPs), since they raise Factor VIII activity 
(FVIII:Ac) in hemophilia carriers and, in vWD patients, OCPs ameliorate 
hemostatic deficiencies, raise Factor VIII/vWF-ristocetin cofactor 
activity, and ameliorate prolonged bleeding time (39,45,52,61). The 
benefits and risks of using estrogen must be considered when prescribing 
oral contraceptives; for example, some will use estrogen for females with 
a history of deep vein thrombosis if taking coumadin (56,62). 
Levonorgestrel-releasing IUD 
The levonorgestrel-releasing IUD (Mirena IUD or Mirena coil) 
releases a small dose of levonorgestrel that has a number of effects and 
benefits, as listed in table 14 (38,56,63,64). One of the benefits is 
improvement of DUB in females with coagulation disorders, though its 
historic link to pelvic inflammatory disease has limited its use in 
adolescent females (52,56,62). 
Other management options 
Various other options have been used in adult females to control irregular 
menstrual     bleeding,     including     danocrine     (Danazol),     GnRH     agonists 
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(buserelin, leuprolide [Depo Lupron], naforelin [Synarel]), D & C 
(dilation and curettage) and hysterectomy (38,65). Danocrine is a 
synthetic hormone prescribed to manage endometriosis, breast cysts, and 
heavy menstrual bleeding in adult females. Danocrine suppresses 
estrogen and prevents menstruation, though ir is teratogenic and can lead 
to masculinization. It has limited research support in adolescents. Also 
with limited research data in adolescent  is the use of GnRH agonists 
used in adult females to stop ovulation.  
Table 14. Effects and benefits of levonorgestrel IUD 
A. Contraceptive effects
• Prevents fertilization
• Interferes with ovum development 
• Interferes with sperm movement and ability to penetrate ovum 
• Inhibits sperm survival
• Helps prevent egg release
• Thickens cervical mucus
B. Benefit
• Effective contraception for 5 years
• Eventual reduction in menstrual flow
• OK for those with coagulation disorders 
• Up to a 90% reduction in bleeding
• 20%-50% with no menses after one year
• Good for those with Mental retardacion/Developmenral
disorders 
• Frequent amenorrhea 
• Decreased dysmenorrhea 
• Decreased premenstrual syndrome 
• Very low rates of infectious complications
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Table 15. Causes of primary amenorrhea 
• HYPOTHALAMlC-INDUCED 
Stress 
Drugs 
Exercise
GnRH deficiency
Obesity 
Eating disorders 
Others 
•  PITUITARY-INDUCED: HYPOPITUITARISM 
Congenital (idiopad1ic) 
Head trauma 
Tumor (prolactinoma) 
Ochers (as hemochromatosis) 
• OVARIAN-INDUCED 
Gonadal dysgenesis
Polycystic ovary syndrome (PCOS)
Tumor 
Resistant ovary syndrome 
Others 
Ovarian failure
Radiation or chemotherapy-induced 
Premature failure 
Autoimmune oophoritis 
•  OTHERS 
Adrenal gland tumor 
Congenital adrenal hyperplasia (complete or partial) 
Androgen insensitivity syndrome (AIS) 
True hermaphroditism 
Hyperthyroidism or hypothyroidism 
Uterine synechiae 
Pregnancy 
Vaginal agenesis 
Transverse or longitudinal vaginal septum that obscruct the outflow 
lmperforate hymen
Cervical agenesis 
Others 
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AMENORRHEA 
Amenorrhea or absence of menstrual flow is divided into primary and 
secondary amenorrhea (66,67). Primary amenorrhea is defined as lack of 
menstruation by age l4 at sexual maturity rating (Tanner stage) 1 (having 
no sexual maturation) or by age 16 with some sexual maturation; lack of 
menses 3-4 years after thelarche may also be considered to be primary 
amenorrhea (1). Primary amenorrhea has a prevalence o f  3 per 100 
adolescents in the United States. Secondary amenorrhea points to menses 
cessation for at least 4 to 6 months after regular menses bas been 
established or for a time equal to a total of three or more previous 
menstrual cycles. Oligomenorrhea (see table 1) is defined as menses that 
occur at intervals over 45 days and are usually irregular as well. Causes 
of amenorrhea and oligomenorrhea are the same in most cases and are 
now considered in the next section. 
Table 16. Clinical classification of amenorrhea in the adolescent* 
I. Primary Amenorrhea with Pubertal (Sex) Delay 
A. Gonadal malformation 
l . Turner syndrome (Gonadal dysgenesis) 
2. Androgen insensitivity syndrome (Testicular feminization 
syndrome) 
B. Hypothalamic-Pituitary Dysfunction 
1.Physiologic Delay (Most common) 
2.Functional Disorders: bypothalamic-induced: such as weight
loss, eating disorders, exercise, stress, others 
3. Organic Disorders: Prolactinoma, Chronic Illness, others 
II. Primary Amenorrhea without Pubertal (Sex) Delay 
A. Pseudoamenorrhea
1. lmperforate hymen 
2. Transverse vaginal septum
B. Mayer-Rokitansky-Kustcr-Hauscr Syndrome -agenesis of vagina, 
cervix, uterus 
C. Polycystic Ovary Syndrome (Hyperandrogenemia Syndromes) 
D. Chronic Illness (including Thyroid Disorders) 
F. Others 
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III. Secondary Amenorrhea 
Pregnancy (most common) 
Hypmbalamic-induced such as weight loss, eating disorders, exercise,
stress, Polycystic Ovary Syndrome (Hyperandrogcnemia Syndromes) 
4. Thyroid Disorders
5. Pituitary disorders (Pituitary adenoma) 
6. Hypoestrogenemia (ovarian dysfunction or ovarian hypofunction)
7. Chronic Illness
8. Others
• Modified and reprinted with permission from: Greydanus DB, Patel DR.  The 
female athlete: before and beyond puberty. Pediatric Clin North Am 
2002;49:553·80. 
PRIMARY AMENORRHEA 
Etiology 
Table 15 lists causes of primary amenorrhea and include physiologic 
delay (constitutional growth delay), chronic illness, Turner's syndrome 
(gonadal dysgenesis), Mayer-Rokitansky-Küster-Hauser syndrome 
(MRKH syndrome), and androgen insensitivity syndrome (1,6,68-71). 
The most common cause is physiologic delay. Primary amenorrhea can 
be seen in those with hirsutism and virilization, such as seen in polycystic 
ovary syndrome (PCOS), mixed gonadal dysgenesis, gonadal 
dysgenesis with virilization, congenital adrenal hyperplasia, ovarian or 
adrenal tumors, true hermaphroditism and others (see table 15).  
Table 16 lists causes of primary amenorrhea based on those with 
pubertal delay and those without pubertal delay. Causes of primary 
amenorrhea that do not usually cause secondary amenorrhea are included 
in table 17. However, there is considerable overlap between disorders       
that cause primary versus secondary amenorrhea and a careful evaluation 
is necessary for both. Table 18 lists causes of hirsuitism and virilization 
in females, while table 19 lists disorders to be distinguished from 
hyperandrogenism. 
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Table 17. Causes of primary amenorrhea and 
not secondary amenorrhea 
Androgen insensitivity syndrome 
Congenital hydrocephalus 
Idiopathic hypopituitarism 
Kallmann's syndrome 
Laurence-Moon-Bardet-Biedl syndrome 
Hermaphroditism 
Mayer-Rokitansky-Kuster-Hauser syndrome (Genital tract agenesis) 
Medical history 
Menarche typically occurs 2-3 years after thelarche with a range of 1 to 5 
years, often between Tanner stage 3 and 4: however, approximately 15% 
occur in Tanner stage 5. Menarche often occurs within a year of the 
mother's menarche. Key questions to explore in an adolescent female 
presenting with amenorrhea is whether pregnancy may have occurred 
( even if  "primary" amenorrhea is being investigated), if there is normal 
or low estrogen stale, if there is evidence of excess androgen production, 
and if there is an anatomically normal genital tract. The medical history 
should review pubertal development carefully and look for evidence of 
congenital anomalies, hernia as an infant, systemic illnesses, excessive 
exercise patterns, and virilization (i.e., hirsutism, clitoromegaly, scalp 
hair thinning, severe acne).  
A careful history of the menstrual pattern is important to obtain, in 
order to distinguish primary from secondary amenorrhea (1). What is the 
sexual history of the patient, looking for previous pregnancies or 
abortions? What is the state of the patient's nutrition? Is there a history of 
endomctrial destruction from a dilatation and curettage (Asherman' s 
syndrome) or stenosis of the cervix from previous vigorous cautery 
because of an abnormal Pap smear? Is there a history of drug abuse, 
since various drugs can lead to amenorrhea, including cocaine, oral 
contraceptives, progestin-only pills, calcium channel blockers, 
cimetidine, phenothiazines, tricyclic antidepressants, metoclopramide, 
and others. 
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Table 18. Causes of hirsutism and virililization in females 
Increased androgen-dependent hair and virilism 
Genetic and familial increased androgen sensitivity 
Androgen excess 
"Psychogenic" hirsutism 
Stress
Schizophrenia 
Exogenous androgens 
Medical 
Hypoplastic anemias 
Growth stimulation  
Adrenal replacement 
Danazol 
Synthetic progestins in oral contraceptives 
Adrenocorticotropic hormone (ACTH) therapy 
Nonmedical 
Bodybuilding and athletic anabolic steroids 
Female to male transsexualism 
Environmental(?) 
Skin contact with male using topical testosterone 
Anabolic steroids given to livestock 
Plant or  microorganism androgens 
Adrenal androgens 
Congenital adrenal hyperplasias 
21-hydroxylase deficiency
Classic 
Late-onset
3-β hydroxysteroid dehydrogenase deficiency
Classic 
Late-onset
11 β -hydroxy lase deficiency 
Classic 
Late-onset 
Adrenal tumors 
Adrenocortical carcinoma 
Testosterone-secreting adenoma 
Adrenal rest adenoma and carcinoma 
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Cushing's disease 
Ovarian androgens 
Polycystic ovary syndrome (PCOS) 
Conditions associated with PCOS 
PCOS with ovarian tumor 
Pineal gland hyperplasia and diabetes 
Congenital lipoatrophic diabetes 
Hyperprolactinemia 
Hyperthyroidism 
Hypothyroidism 
Androgen-secreting cysts and hyperplasias 
Stromal hyperplasia and hypcrtheocosis 
Solitary follicle cyst 
Hyperreaction luteinalis of pregnancy 
Androgen-secreting ovarian tumors 
Arrhenoblastoma (androblastoma) 
Thecoma-fibroma group tw11ors 
Granulosa cell tumors 
Lipoid cell rumors 
Gyoandroblastorna 
Epithelial tumor 
Luteoma of pregnancy 
Testicular androgens in XY females 
5-α reductase deficiency 
Mixed gonadal dysgenesis 
True hermaphroditism 
17-β bydroxysteroid dehydrogenase deficiency 
Other rare intersex conditions 
Source: Reprinted with permission from: Greydanus DE, Shearin RB. 
Adolescent sexuality and gynecology. Philadelphia. PA: Lea & Febiger, 
1990:176. 
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      Table 19.Disorders to be distinguished from hyperangrogenism 
Hirsutism 
Generalized hypertrichosis 
Idopathic 
Familial 
Drugs and toxins 
Diphenylhydantoin 
Minoxidil 
Diazoxide 
Phenothiazines 
Cyclosporine 
Hexacblorobenzene poisoning 
Streptomycin 
Penicillaroine 
Cobalt
Acrodynia 
Danazol 
Rare genetic syndromes 
Hypertrichosis lanuginosa or universalis 
Hepatic and erythropoietic porphyrias 
Laurence-Moon-Biedl syndrome 
Morgagni-Stewart-Morel syndrome 
Seckel bird-headed dwarfism 
Cornelia de Lange's syndrome 
Trisomy E 
Hurler's syndrome 
Chronic systemic illness 
Chronic renal failure 
Dermatomyositis  
Cancer 
Chronic central nervous system dysfunction 
Cerebral palsy 
Spina bifida 
Multiple sclerosis 
Postencephalitic slates 
Others 
Endocrine Disorders 
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Hypothyroidism 
Growth hormone-secreting pituitary adenoma 
Hyperprolactinemia 
Hirsutism 
Generalized hypertrichosis 
Chronic malnutrition 
Anorexia nervosa 
Localized hirsutism or  hypertrichosis 
Hairy nevus (several types) 
Broken extremity bone 
Extremity lymphedema 
Repeated local trauma 
Clitoromegaly without ambiguity 
Clitoral priapism 
Pibroma of clitoris 
Chronic vulvovaginitis 
Acne 
Cushing's syndrome 
Exogenous exacerbating agents 
Androgenic steroids 
Synthetic progestins 
Glucocorticoids 
Lithium 
Diphenylhydantoin 
Barbiturates Isoniazid 
Rifampin 
Iodides 
Kelp and other seaweed 
Bromides 
Persistent unpleasant body odor without apparent disease 
Foreign body (especially in the nose or vagina) 
Genetic disorders of organic acid metabolism 
Dietary spices 
Ttimethylaminuria 
Poor hygiene 
Source: Reprinted with permission, from: Greydaaus DE, Shearin RB. 
Adolescent sexuality and gynecology. Philadelphia: Lea Pebiger, 1990: 177. 
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Physical examination 
A careful physical examination is important, looking for tall stature (46 
XY karyotype), short stature (46,X0 in Turner's syndrome), hypertension 
(with delayed sexual maturation as in 17-α-hydroxylase deficiency), 
bradycardia (as in hypothyrodism or anorexia nervosa), anosmia 
(Kallmann's syndrome), visual field defects with papilledema (brain 
tumor), or cachexia (anorexia nervosa) (1,6). 
A careful gynecologic examination is important in identifying the 
cause of primary amenorrhea. The breast examination may reveal small, 
pale areolae (as in anorexia nervosa) or chronic estrogen decrease (as in 
Turner's syndrome or other causes of ovarian failure). If amenorrhea is 
present with galactorrhea, consider a prolactin-producing pituitary 
adenoma. The presence of sparce or absent pubic hair with full breast 
development suggests androgen insensitivity syndrome with a 46 XY 
karyotype. Youth with hirsutism, severe acne, enlarged clitoris, and scalp 
hair thinning (frontotemporal) suggests excess androgen production. 
Table 20. Vaginal cytological maturation index 
l. Use Pap smear fixative for the vaginal smear 
2. One point is given for each superficial cell, 1/2 point for each 
intermediate cell, and 0 points for each parabasal cell.
3. A score > 40 suggests some estrogen effect
4. A score of 50-60 is found in pubertal females
5. 0-30 is seen in prepubertal females
6. 31-55 ref1ects a hypoestrogenic state of adult females 
Examine the external genitalia and look for an enlarged clitoris 
(androgen excess), an abnormal hymen (imperforate or cribriform), or 
evidence of estrogen deficiency (thin, pink, vulvar mucosae). Look at the 
cervical mucus and evaluate the Vaginal Cytological Maturation Index 
(see table 20). If there is copious, watery mucus that reveals spinnbarkeit 
by ferning an air-dried slide using microscopy, this suggests a high-    
estrogen state as noted in the late proliferative state before ovulation. A 
thick and tenacious cervical mucus that dries in amorphous clumps 
without ferning on  microscopy suggests a  progestin effect  as seen in the 
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secretory state after ovulation,  pregnancy, or due to a  progestin-
containing pill. 
Look for a transverse vaginal septum and presence of a cervix during 
the pelvic examination. If there is a history of primary amenorrhea, 
establish vaginal patency with moistened cotton or dacron-tipped 
applicator or a moistened gloved finger. If a bimanual exam is possible, 
look for a mass (consider pregnancy or hematometra); also look for 
ovarian enlargement, as in polycystic ovary syndrome. A rectal exam 
may be necessary to help establish the presence of a cervix or find a mass 
proximal to an obstructed vaginal canal (as in a hematocolpos). 
Detection of anatomical genital defects results from genital 
inspection and pelvic/rectal examination. A karyotype is of1en needed in 
cases of primary amenorrhea. Definitive procedures include sonography, 
MRI, and laparoscopy. The patient should be screened for additional or 
associated congenital anomalies if a genital anomaly is present; these 
include musculoskeletal, cardiac, and/or renal anomalies in some cases. 
Endocrinological and gynecological consultation is often necessary for 
those with primary amenorrhea. Tables 21 and 22 outline basic 
laboratory testing for adolescents with amenorrhea. 
Mayer-Rokitansky-Küster-Hanser Syndrome 
(MRKH Syndrome) 
The MRKH syndrome (see table 22) or Müllerian agenesis is a 
congenital condition in which there is absence of all or part of the uterus 
and vagina as the cause of primary amenorrhea (1). Typically there is 
uterine agenesis (or rudimentary uterine development) with absence of 
the upper two-thirds of the vagina in association with the presence of 
ovaries, fallopian tubes, breasts, pubic hair, normal female hormonal 
patterns, and a normal female karyotype (46, XX). Over half may have 
urinary tract anomalies while 25% have vertebral column malformations. 
The differential diagnosis includes the androgen insensi1ivity syndrome 
(see table 22) and confirmatory diagnostic tests include the pelvic 
ultrasound, MRI, and laparoscopy. 
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Table 21. Laboratory Testing for Amenorrhea in Adolescents (to 
be used selectively after thorough clinical examination) 
Pregnancy Test 
Hormonal investigation: 
LH & FSH: Increased in ovarian failure/dysgenesis; normal or 
decreased in others 
Thyroid hormone levels 
Prolactin levels 
If virilization/hirsutism present: DHEAS, LHJFSH ratio 
(nl:<2.5: 1), testosterone (total and free) 
Level of estradiol & progesterone and/or 
Vaginal smear to evaluate for epithelial cell estrogenization 
Pelvic ultrasound to define anatomy (uterine hypoplasia) 
Vaginoscopy 
Bone age 
Chromosome evaluation 
Anti-ovarian antibodies 
Head CT/MRI 
Pelvic/abdominal MRI 
Renal ultrasound/IVP 
Laparoscopy 
Other vaginal outflow tract abnormalities 
The female with an imperforate hymen is noted in 1 in 1,000 and 
presents with primary amenorrhea and cyclic pelvic pain. There is a 
bulging, bluish hymenal membrane and even retrograde menses that may 
predispose to endometriosis. Management involves early diagnosis with 
incision and drainage of the imperforate hymen under anesthesia (72,73). 
Transverse vaginal sepum is noted in 1 in 80,000 and the obstruction is 
due to a septum at the junction of the upper and middle thirds of the 
vagina. Retrograde menstruation may occur, leading to endometriosis. 
Similar problems can occur with longitudinal vaginal septum, when the 
septum is attached to the vaginal wall on the side of the cervix, thus 
obstructing outflow. 
 ; 
Gynecologic 
Table 22. Gynecological disorders of adolescent females 
Special comments Differential diagnosis 
disorder 
Amenorrhea 
(Primary) 
Physiologic is the main cause; 
MRKH syndrome assoc. with 
Renal abnormalities and Spinal 
malfomrations. 
Short stature with delayed sexual maturation:   
Turner syndrome; delayed sexual maturation
+ hypertension seen in 17-α-hydroxylase 
deficiency; Swyer syndrome; absencc of
smell sense suggests Kallmann syndrome; 
visual field deficits suggests brain tumuor. 
Physiologic 
Imperforate: hymen 
Mayer-Rokitansky-Kuster-Hauser (MRKH) 
Syndrome; 
Turner syndrome (45,XO and mosaicism)
   Chronic Illness 
Hypothalamic: Stress. eating disorders, e.xe:rcise, 
depression; 
Androgen insensitivity syndrome (46 XY); Swyer 
syndrome; others: See Text 
Amenorthea 
(secondary) 
Pregnancy; lactation; 
Stress, eating disorders, 
Chronic illness, 
Exercise induced, 
prolactinoma (headaches, visual field deficits. 
galactorrhea) 
PCOS (polycystic ovary syndrome); 
See text. 
Pregnancy is the main cause: history of 
sexual activity- may present with a midline 
"pelvic mass"; causes of oligomrnorrhea and 
secondary amenorrhea are  essentially the 
same. A1so important is history of dietary 
habits, exercise, stress: acne and hirsutism 
suggest elevated androgen levels; Athlete  
Triad Syndrome: amenorrhea, dysfunctional 
eating patterns, osteopenia-porosis. 
Laboratory          
testing 
Serum 
gonodotropins 
(FSH, LH), prolactin, 
TSH: 
Pelvic Ultrasound MRI, 
Head CT/MRI Renal 
ultrasound/IVP 
(intravenous pyelogram: 
Karyotype 
Laparoscopy 
Dysmcnorrhea Physiologic Pelvic pain during normal 
ovulatory menstruation; no underlying pelvic 
pathology. 
May also see gastrointestinal symptoms. 
(Primary)
Pregnancy
Test (β-hCG) 
Progesterone  challenge    
Serum estrogen, FSH,  LH: 
bone mineral            
densitometry: 
Serum prolactin                
Thyroid screen; 
Head CT 
Dysmenorrhea 
(Secondary) 
laparoscopy 
STD screen 
Pelvic Ultrasound; MRI 
Endometriosis 
Pelvic lnflammatory Disease 
Reproductive tract anomalies 
Pelvic adhesions
Cervical stenosis          
Ovarian masses
Pelvic congestion syndrome 
Rule out Urinary Tract or 
Gastrointestinal causes 
Dysfunctional 
Uterine 
Bleeding 
(DUB) 
Anovulatory bleeding; 
Pregnancy, ectopic pregnancy;  coagulation 
disorders (as von Willebrand disease, others), 
anatomic lesions, endometrial
pathology;  cervicitis or cervical dysplasia; pelvic 
inflammatory disease; ovarian cysts; polycystic 
ovary syndrome: severe stress, tapid or severe 
weight gain or loss, drug abuse; see text. 
CBC, platelets, beta- 
HCG, Pap smear, PT, 
PTT, bleeding time, 
other coagulation 
disorders screening; D- 
2 l progesterone; thyroid 
screen: S'TD screen; 
ultrasound (transvaginal;  
pelvic), MRI; 
hysterosoopy. 
Ectopic See DUB differential β-hCG; pelvic 
Pregnancy 
headache, myalgia, sweating. 
May be seen at menarche or 3+ years post-
menarche.  
Menstrual calendar useful to get accurate 
history of rnenstrual pattern;  get sexual  
activity history; 
Establish presence/absence of ovulation: 
basal body temperature charts,  serum 
progesterone, urinary luteinizing hormone 
(LH) and possibly endometrial biopsy. 
role out an STD: virilization evaluation 
necessary if hirsutism present. 
Pain with history of secondary amenorrhea  
often with vaginal bleeding. ultrasound 
Endometriosis Presentation in adolescence not the same as in  Laparoscopy 
Laparotomy 
Mittelschmertz See secondary dysmenorrhea Menstrual calendar 
adults.  May have acyclic pain, abnormal 
uterine bleeding. GI symptomatology        
Pain  associated with ovulation in the middle 
of a menstrual cycle.  May last 1-3 days and 
See secondary dysmenorrhea 
Ovarian Masses 
Pelvic. 
lnflammatory
Ovarian cysts 
Ovarian tumors (benign, malignant) 
Polycystic ovary syndrome 
Ectopic Pregnancy 
Tubo-ovarian mass 
Ectopic pregnancy, appendicitis, pyelonephritis, 
ovarian cyst, septic abortion, others. 
Disease 
Pregnancy test 
Pelvic Ultrasound 
Non-specific: 
white blood cells on 
saline prep; elevated 
ESR; elevated CRP: lab 
evidence of Neisseria 
gonorrhoeae or 
Chlamydia trachomatis;  
Specific Criteria 
Positive biopsy: 
Endometrium 
showing         
endometritis;      
Evidence of PID 
on laparoscopy; 
be mild to severe. 
Presents with a lateral location; abnormal 
menses 
STD that can lead to uterine tenderness, 
adnexal tenderness, tenderness on cervical 
motion, muco-purulent vaginal or cervical 
discharge; can see fever (T > 101 F, 38.3 C); 
polymicrobial disorder of the upper genital 
tract often precipitated by Neisseria 
gonorrhoeae, Chlamydia trachomatis, others 
(Gardnerella vaginalis, Mycoplasma hominis, 
Ureaplasma urealyticum, Haemophilus 
influenzae, coliforrns, cytomegalovirus, 
peptostreptococcus, and other anaerobes).  
Can involve various combinations of
endometritis, salpingitis, tubo-ovarian   
abscess, and pelvic peritonitis. Complications 
include infertility,  chronic pelvic pain. 
ectopic pregnancy. 
ultrasound or     
MRl showing   
that fallopian 
tubes are thick and 
filled with fluid; 
may be free fluid  
in the pelvis or a 
tubo-ovarian 
complex. 
Polycystic ovary Insulin resistance with hyperinsulinemia. Other causes of hyperandrogenism; HAIR-AN LH, FSH, T -4, prolactin, 
syndrome (PCOS; 
hyperandrogenemia 
syndrome  
hyperandrogenemia, and chronic anovulation; can 
see irregular menses (secondary amenorrhea, 
oligomenorrhea, DUB), 
hirsutism, possible virilization, variable 
obesity, acanthosis nigricans, possible 
bi1ateral enlarged ovaries. 
Syndrome; Congenital adrenal hyperplasia (11B-
hydroxylase, 
21-hydroxylase, 3B-hydroxysteroid dehydrogenase 
deficiency); Cushing's disease, hyperprolactinemia, 
Ovarian or adrenal tumor: Mixed gonadal 
dysgenesis (4SX/46XY, 4SX/46XX/46XY): 
Gonadal dysgenesis with virilization; true
hermaphroditism 
Variety of symptoms start before and end 
with menses 
testosterone (total and 
free), insulin level; lipid 
profile: 
dehydroepiandrosterone 
sulfate (DHEAS): 17-α-
hydroxyprogesterone;    
24 hour urine for free 
cortisol; dexamethasone 
suppression test;  Pelvic 
ultrasound 
DSM-IV (2000) criteria 
for PMDD 
Premenstrual dysphoric disorder (PMDD); 
depression; anxiety; others, depending on the 
presenting symptoms; see text.
Abbreviations: CBC: complete blood count; Pap, Papanicolaou smear; STD: sexually transmitted disease; MRI: magnetic resonance 
imaging; GI, gastrointestinal; ESR, erythrocyte sedimentation rate; F; Fahrenheit; C: Centigrade; HAIR-AN: hyperandrogenism, 
hirsutism, insulin resistance, acanthosis nigricans; DSM-IV: Diagnostic Statistical Manual-4th Edition (American Psychiatric 
Association); PT: prothrombin time; PTT: partial thromboplastin time. Reprinted with permission from Greydanus DE.                       
Feinberg AR, Patel DR, Homnick DN, eds. The Pediatric Diagnostic Examination. New York: McGraw-Hill, 2008. 
Premenstrual 
Syndrome 
(PMS) 
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Others 
In male pseudohermaphroditism there is a 46 XY karyotype and a female 
phenotype with uterovaginal atresia and functioning testicular tissue. 
Leydig cell agenesis occurs due to defective LH receptors and this leads to 
inadequate androgen secretion. Various autosomal-recessive disorders are 
noted with ambiguous genitalia. In 17 -a-hydroxy lase deficiency, there 
is an individual with a female  phenotype that has breast tissue, 
primary amenorrhea, and often, hypertension. 
In the androgen insensitivity syndrome (formerly called the testicular 
feminization syndrome), the individual has a female phenotype with full 
breast development and scant or absent pubic and axillary hair. The 
vagina ends in a blind pouch and testes are present. There is typically a 
history of a herniorrhaphy as an infant. There is also an increased level of 
LH, testosterone, and estradiol; this individual is at increased risk for a 
gonadal neoplasm, though this risk is lower than that seen in 46 
XY gonadal dysgenesis. 
SECONDARY AMENORRHEA
The most common underlying cause of secondary amenorrhea (after 
pregnancy) in an adolescent is anovulation, resulting from inhibition of 
FSH and LH because of various factors that influence the hypothalamus 
(see table 22) (1,6,9,69,74). This "hypothalamic" amenorrhea can be due 
to major weight loss or gain, increased stress, systemic illness, excessive 
physical activity as noted in competitive sports, and others. Secretion of 
steroid and neuroendocrinc hormones can resemble patterns noted in 
early puberty or even pre-puberty with low gonadotropin levels and 
reduced sex hormones (androgens and estrogen). 
Other factors inducing amenorrhea include pregnancy, immaturity, 
thyroid disorders (hyper or hypothyroidism), polycystic ovarian disorder, 
anorexia nervosa (even before severe weight loss develops), other 
chronic illnesses, various medications, illicit drugs, prolactinoma, 
pituitary destruction from infiltration or infarction, Asherman's 
syndrome (uterine synechiae) and others (sec table 22). 
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As noted, overlap and confusion between causes of p1imary versus 
secondary amenorrhea may occur, since both can be due to dysfunction of 
the hypothalamic-pituitary-ovarian axis. The history of previous 
menstruation suggests the presence of a patent uterus and vagina, thus 
eliminating the diagnosis of a congenital anatomic disorder of the uterus 
and/or vagina (i.e, Mayer-Rokitansky-Kuster-Hauser syndrome). Causes 
of secondary amenorrhea and oligomenorrhea are essentially the same. 
Table 23 provides a suggested plan for evaluating the cause of secondary 
amenorrhea (see table 23 and figure 3). Table 24 provides a plan for 
evaluation of an ovarian versus adrenal etiology in an adolescent with 
hyperandrogenism and oligomenorrhea or amenorrhea.  
Table 23. Plan for evaluation of secondary amenorrhea 
Pregnancy should always be considered and ruled out, even with denial 
of sexual activity and history of only one late or  absent menstrual 
period. 
The state of estrogenization should be determined and determine if 
estrogen priming of the endometrium is occurring using the vaginal 
cytologic maturation index (see table 20). Look at microscopic 
evidence of ferning (denoting anovulation) in an air-dried slide of 
cervical mucus. 
Consider a progestin challenge. If there is no pregnancy or chronic 
illness present, give medroxyprogesterone acetate, 10-20 mg/day, PO,    
for 5 days, or a single dose of progesterone-in-oil, 100 mg, IM. If a 
withdrawal bleeding occurs, this suggests  the hypothalamic-pituitary   
axis is able to respond, at least to some extent, there is an 
endometrium, and the genital outflow tract is patent. The usual 
situation is either hypothalamic suppression or reversible chronic 
anovulation. Mild hypoestrogenism is suggested by a scant bleeding while 
no bleeding at all suggests such conditions as outflow-tract 
agenesis or obstruction, loss of the endometrium, ovarian failure, or 
chronic hypoestrogenism from various causes. The presence of chronic 
hypoestrogenism implies the need for estrogen replacement. If there is a 
non-response along with the presence of normal or low FSH, this 
suggests major dysfunction of the hypothalamic-pituitary axis. 
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If the patient has normal estrogenization and normal withdrawal 
bleeding with the progestin challenge, the patienl and parents can be 
reassured that the reproductive tract is normal. Help her deal with such 
underlying factors as stress, extreme exercise, major weight gain or  
loss and others. If the rest of the evaluation is normal, one can adapt a 
"watch and wait" process in which the patient is seen periodically (as 
every 3-6 months) to await the resumption of normal menstruation. A 
repeat or periodic progestin challenge test may be helpful in select 
situations; it may also prevent endometrial proliferation secondary to 
unopposed estrogen that may lead to dysfunctional uterine bleeding (as 
menometrorrhagia). Oral contraceptives may be used without fear that 
they will delay the resumption of normal menstruation when stopped. 
Oral contraceptives can also be used to manage dysfunctional uterine 
bleeding if this develops. 
Oligomenorrhea is a common process in adolescent females and 
extensive evaluation is not usually needed in an otherwise healthy 
patieot who is within 2 years of her menarche. Specific evaluation may 
proceed, however, if the oligomenorrhea continues over 2 years from 
menarche, develops for over 6 months in a youth with previous normal 
menses, or if the initial evaluation suggests an underlying chronic 
illness. 
If the cause of the amenorrhea or oligomenorrhea is not clear after the 
above evaluation, a more extensive evaluation is necessary looking for 
various medical conditions and/or mental health issues (i.e., stress) that 
starts with a full history and complete physical examination. The 
evaluation includes pelvic and rectal exams looking for potential 
anatomical or physiologic disorders (Tables 15-19). It is very important   
to identify the presence or absence of uterine or adnexal mass(es). A 
pelvic ultrasound and MRI may be necessary to confirm normal or 
abnormal anatomy while important laboratory data supportive of the 
evaluation are noted in table 21. A head CT or MRI may be needed to 
rule out a CNS tumor especially if galactorrhea or various neurological 
signs are present 
Look for hyper/hypothyroidism and galactorrhea. An abnormal TSH 
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screen should prompt further evaluation for thyroid dysfunction that                
can lead to altered menstrual status.  Increased prolactin levels suggest 
hyperprolactinemia as the cause of the menstrual dysfunction, though 
increased prolactin can also be seenn in hypothyroidism, hirsutism, and 
PCOS as well. Fasting prolactin levels can be increased without 
galactorrhea being present Prolactin levels over 50-100 ng/rnl warrant          
a head MRI or CT to screen for a prolactinoma. Prolactin levels over            
70 mg/ml are typically seen with amenorrhea, though screening for 
chronic renal failure should also be done. Low levels of serum 
prolactin in cases of amenorrhea are consistent with hypothalamic 
disorder induced by stress.  
It is also important to evaluate this patient with .secondary amenorrhea     
for dysfunction of the hypothalamic-pituitary-ovarian axis. An FSH 
and LH level can be obtained for perfoming the progestin challenge          
test, though some clinicians will not perform this screen unless there is       
no withdrawal bleed after the progestin is given. Since the added 
progestin can suppress the gonadotropins, one should wail at least 7 to       
10 days after the progestin challenge test to screen for levels of FSH           
and LH. If the FSH is over 40 mlU/L, and the LH is over 25 mlU/L,            
this indicatcs a hypergonadotropic condition suggesting the presence of 
ovarian failure essentially in proportion to the degree of FSH/LH 
increase; further evaluation is necessary, as reviewed below. 
It is also important to obtain a karyotype in these patients, looking for such 
conditions as 46,XY or 45,X or 45.X/46,XX. If a 46 XY 
karyotype is found, perform a laparoscopy while an autoimmune 
disease evaluation is important to pursue if 45,X/46,XX is found 
(46XY could be the diagnosis in primary, not secondary ameonorrhea).       
It is often difficult to separate low from normal FSH/LH levels,
particularly in young adolescents. However, low or normal 
gonadotropin levels in the presence of a normal progestin challenge
suggest a diagnosis of reversible hypothalamic dysfunction with 
anovulatiou, due to stress or early PCOS. Gonadotropin levels that are 
unmeasurable suggest irreversible deficiency of the hypothalamus or
the pituitary. Low or normal gonadotropin levels in the presence or 
absence of a withdrawal bleed suggest an underlying endocrinologic 
disorder of either hypothalamic or pituitary origin. Consider PCOS if
363 Menstrual Disorders in Adolescent Females 
the LH is increased and the FSH is normal or low; however, in some 
PCOS, the LH is also normal. An elevated LH in contrast to the                
FSH level is also found in hyperestrogenism. If the patient with 
amenorrhea bas normal estrogen status, this suggests that the ovaries    
are functional. Low estrogen levels are consistent with ovarian failure         
if there is also high FSH/LH or pituitary deficiency with low FSH/LH.      
If hypothalamic dysfunction occurs, the estradiol levels may be near the 
lower margin of normal with low FSH/LH levels. Estradiol levels can be 
mildly increased or normal in PCOS or other conditions of 
hyperandrogenism. If hirsutism is noted, screening for hyperandrogen 
states is necessary, as reviewed in the text  
If oligomenorrhea or amenorrhea develops in the presence of a 
hyperandrogenic state, evaluate for an ovarian versus adrenal etiology, as 
reviewed in table 24. 
Perplexing causes of amenorrhea in youth may require consultation 
with experts in endocrinology, gynecology, or neurology. Management 
depends on the underlying cause and is reviewed below. If transient 
hypothalamic suppression is found, reassurance and patience is the usual 
recommendation. It is important to consider various factors that influence 
menses (see table 25). If systemic disorders (including endocrine conditions) 
or tumors are found, again, referral to appropriate specialists is needed. 
Polycystic ovarian syndrome (PCOS) is reviewed below. If there is primary 
failure of the ovaries, hormonal replacement is needed, as reviewed below. 
Comment is now provided on specific medical causes of amenorrhea. 
HYPOTHALAMIC AMENORRHEA 
Hypothalamic disorders causing amenorrhea include constitutional 
growth delay, congenital GnRH deficiency, and hypothalamic 
amenorrhea (1,9). Congenital GnRH deficiency can be seen in the 
Kallman syndrome with hypogonadism and anosmia. Hypothalamic 
amenorrhea results from such causes as psychological stress, poor 
nutrition, chronic illness,  and strenuous exercise.  The amenorrhea is due 
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to disruption of GnRH pulsatile release that leads to reduced levels of 
FSH, LH, estradiol, and prolactin along with bypercortisolism. Stress that 
can induce amenorrhea can include depression, anxiety, and illicit drug 
use or withdrawal from drug use. Pseudocyesis (false pregnancy) is an 
extreme example in which LH and prolactin secretion are high enough to 
sustain luteal function and even galactorrhea. The inhibition of 
hypothalamic neuroendocrine function seen in systemic illness (see table 
26) is similar to that described in starvation along with additive factors of
stress and altered steroid metabolism.
Menstrual dysfunction may be seen in female adolescents with obesity 
because of chronic anovulation. The underlying mechanisms of the 
oligomenorrhea and secondary amenorrhea include increased estrogen 
levels because of aromatization of androgens from excess 
adipose tissue; in addition, there is complex interplay of hyperinsulinism 
and hyperandrogeuism, more characteristically seen in PCOS, but seen to 
some extent in obesity. Stress noted in some with obesity, can also 
contribute to menstrual disruption. Anovulation and obesity can also be 
secondary to underlying hypothalamic disruption seen in the Prader-Willi 
syndrome or hypothyroidism. If the obese individual has no underlying 
medical illnesses, weight loss can lead to restoration of menstruation.  
ANOREXIA NERVOSA 
Menstrual irregularities can develop in females with eating disorders, 
such as anorexia nervosa and bulimia nervosa (1,9,75-77). Amenorrhea 
may develop with or preceed significant weight loss in the female with 
anorexia nervosa and menstruation may not return until after the weight 
has been normalized. Estrogen deficiency along with low calcium dietary 
intake often leads to osteopenia or even osteoporosis in these patients. 
Given that adolescence is the age during which peak bone mass is 
acquired, there may be severe consequences for future bone health. Bone 
densitometry should always be part of the evaluation; calcium 
supplementation and in some cases OCP's can be used until weight 
normalization and stabilization occurs (see below text on the female 
athlete triad) (78). 
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Used and adapted with permission from:  Joffe A,  Blythe MJ.  Handbook  of 
adolescent medicine. Adolesc Med 2003;14(2):296, figure 2; Greenfield TP. 
Blythe Ml. Menstrual disorders in adolescents» In: Greydanus DE, Patel 
DR, Pratt HD, eds. Essential adolescent medicine. New York, McGraw-Hill, 
2006:600. 
Figure 3. Evaluation of secondary amenorrhea and oligomenorrhea in the 
adolescent patient. 
Trial
medroxyprogesterone,
10 mg x 10 days
 +/-   
Withdrawal,
-   
Withdrawal,
  +
Withdrawal, 
  normal labs
Refer for
treatment
LH/FSH,
estradiol
Menstrual calendar
Reevaluate in 1-3
  Treat or refer
appropriately
  Consider evaluation
for
  Abnormal 
cycles
Normal cycles 
Menstrual calendar
Reevaluate in 1-
3 months
366           Donald E. Greydanus, Hatim A. Omar, Artemis K. Tsitsika et al. 
OTHER HYPOTHALAMIC AND PITUITARY DISORDERS
Hypogonadotropic anovulatory amenorrhea can develop because of 
hypothalamic   destruction   by  infarction,   tumor   infiltration,    or   trauma 
(1,9). Though amenorrhea may be the initial or presenting complaint, 
neurological  symptoms   and/or   evidence  of  other   hormone   deficiencies 
may be seen, together with low levels of gonadotropins (FSH, LH) and      
end-organ    hormones    (estrogen,    testosterone).        Signs      of     estrogen 
deficiency are typically less evident than that seen with primary ovarian 
failure.  
Table 24. Evaluation of ovarian versus adrenal etiology in an 
adolescent with hyperandrogenism and oligomenorrhea
or amenorrhea* 
Measure the scrum or plasma testosterone, free testosterone, and 
androstenedione.  
In functional ovarian or adrenal hyperandrogenism, the total 
testosterone may be normal but the free testosterone and androstenedione 
are increased. If the total testosterone is over 200 ng/dL, suspect an 
ovarian or adrenal virilizing tumor and obtain imaging studies. 
Measure the DHEAS. If the levels arc over 600 µ/dL, suspect an adrenal 
rumor and obtain imaging studies. 
If the etiology remains unclear, obtain a dexamethasone suppression test. 
using an oral dose of 1 mg/m2 daily in divided doses for 5.7 days,
Measure the plasma free testosterone, DHEAS and cortisol both before     
and after administration: 
Suspect PCOS if the free testosterone is not suppressed, but the cortisol     
and DHEAS are. 
If neither the free testosterone nor the cortisol is suppressed, consider:   
an adrenal virilizing tumor, Cushing's syndrome, or noncompliance. 
If the free testosterone is normally suppressed. then obtain an ACTH 
stimulation test to rule out congenital adrenal hyperplasia (CAH). 
Abbreviations: DHEAS = dihydroepiandrosterone sulfate; PCOS = polycystic ovary
        syndrome; ACTH = adrenocorticotropic hormone. •
*Reprinted, with permission, from;  Greydanus DE. Breast and gynecological
disorders.  In: Hofmann AD, Greydanus DE, eds. Adolescent medicine,  3rd ed. 
Stamford. CT: Appleton Lange. 1997:541. 
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Table 25. Influences on the menstrual cycle 
Age 
Weight and Height 
Physiologic and sex development 
Psychological stress 
Nutritional deficiencies 
Genetic predisposition 
Percent body fat 
Amount of exercise 
Chronic Illness 
Medications (prescription or over the counter) 
Race
Others 
Table 26. Chronic illnesses that induce hypothalamic amenorrhea 
Cancer (including chemotherapy and radiation) 
Celiac Disease 
Chronic renal failure 
Cystic fibrosis 
Diabetes mellitus (poorly controlled) 
Inflammatory bowel disease 
(Growth issues and amenorrhea may arise before bowel symptoms) 
Sarcoidosis 
Sickle cell disease 
Systemic lupus erythematosus (other rheumatoid disorders) 
Thyroid disease 
Tuberculosis 
Other systemic illnesses 
If gonadotropins are very low (i.e., <10 IU/L), image the sella turcica  
to look for a lesion of the anterior pituitary or hypothalamus causing the 
amenorrhea. Trauma or tumor can cause disruption of the pituitary stalk 
resulting in pubertal disruption including growth delay; if this occurs 
after puberty is finalized, findings include amenorrhea, galactorrhea, 
diabetes insipidus, hypoadrenalism, and hypothyroidism.  The most 
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common tumor that is involved is a craniopharyngioma that can present 
with headaches, visual field defects, and dysfunction of the 
hypothalamus. A head MRI or CT will identity the tumor. 
The most common infiltrative disorders of the hypothalamic-
pituitary area are central nervous system leukemia and histiocytosis X; 
others include tuberculosis, sarcoidosis, head trauma, hemochromatosis, 
and postpartum necrosis. With the exception of craniopbaryngiomas, 
intraspinal tumors cause headaches and abnormal neurological findings 
more often than they do amenorrhea. Also, craniospinal irradiation for 
cancer can lead to hypothalamic-pituitary dysfunction. The empty sella 
syndrome has rarely been noted in adolescents. Prolactin levels should be 
measured in chronic menstrual dysfunction, especially if galactorrhea 
develops. Prolactin secretion disorders arc noted in 15% of adult females 
with amenorrhea. and the degree of elevated prolactin is associated with 
the degree of menstrual dysfunction. Prolactin levels over 70 ng/L are 
associated with amenorrhea, though the amenorrhea is not related to the 
presence or severity of galactorrhea.  
PRIMARY AND SECONDARY OVARIAN FAILURE 
Increased FSH and LH levels are noted in hypergonadotropic 
hypogonadism as reflected in the ovarian failure of gonadal dysgenesis 
(Turner Syndrome) (79-82) effects of radiation or chemotherapy, and 
autoimmune oophoritis (1,3,9). Approximately 25% of females with 
primary amenorrhea have gonadal dysgenesis. Those with the 45,XO 
karyotype have classic features, including short stature and 
hypoestrngenism with failure of secondary sexual development (see table 
27). The 45,X/46,XX karyotype may have few somatic defects other than 
short stature, and their ovaries may allow ovulation and pregnancy prior 
to ovarian failure. 
The development of amenorrhea and loss of estrogenization after a 
few or some menstrual cycles also occurs in ovarian failure due to 
irradiation or chemotherapy (i.e., vincristine, cyclophosphamide, others) 
for management of cancer and also in the rare situation of premature 
menopause. The combination of both chemotherapy and radiation is 
especially toxic to ovarian function.  Premature  menopause  may occur as 
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a feature of an autoimmune, multiple endocrine syndrome with 
antiovarian antibodies or even as an isolated disorder. It may also be seen 
in resistant ovary syndrome, as well as with various collagen vascular 
disorders or autoimmune endocrinopathies, such as diabetes mellitus, 
myasthenia gravis, hyperparathyroidism, thyroiditis, Addison disease, 
pernicious anemia, or vitiligo. Management of ovarian failure includes 
hormone replacement (estrogen and progesterone) along with 
counseling about self-image, infertility, and sexual functioning (81,82).  
Table 27. Features of Turner syndrome* 
Short stature (usually does not exceed 142 cm) 
Sexual infantilism with streak ovaries (may have slight amount of 
pubic hair) 
Turner facies (fish mouth, low-set ears. malformed ear lobes, 
epicanthal folds, micrognathia) 
Short, webbed neck with low hairline 
Cubitus valgus (wide carrying angle of forearm) 
Fingernail anomalies 
Shield chest with broadly spaced, hypoplastic nipples 
Abnormal hearing and vision (including color blindness) 
Cardiovascular disorders (hypertension, coarctation of the aorta,   
aortic stenosis, bicuspid aortic valve) 
Various renal anomalies 
Multiple pigmented nevi 
Associated with recurrent otitis media, diabetes mellitus, chronic 
lynmphocytic thyroiditis 
Features in infancy: short birth length, 1 ymphedema of hands and feet, 
loose posterior neck folds 
Hirsutism if component of the Y chromosome is present 
*Reprinted, with permission, from: Greydanus DE. Breast and gynecological 
disorders. In: Hofmann AD, Greydanus DE, eds. Adolescent medicine. 3rd 
ed. Stamford, CT: Appleton Lange, 1997:339. 
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ENDOCRINE DISORDERS 
Excessive production or major deficiency of the major hormones may lead to 
significant disruption of the complex menstrual cycle either       
because of interference with neuroendocrine feedback and/or negative 
impact on the overall health of the adolescent female (1,3,9). This 
hypothalamic dysfunction can lead to anovulation with dysfunctional  
uterine bleeding or amenorrhea. Thus, menstrual dysfunction can be seen   
in such endocrine disorders as hyperthyroidism, hypothyroidism, 
Addison disease, Cushing syndrome, late-onset congenital adrenal 
hyperplasia (21-hydroxylase deficiency), hyperprolactinemia, Prader-  
Willi syndrome, Laurence-Mood-Biedl syndrome and others. 
Amenorrhea is typically seen with hypothyroidism, while 
dysfunctional uterine bleeding (DUB) is often noted with 
hyperthyroidism. Hyperpigmented skin folds and pressure areas are seen 
in Addison Disease and vitiligo is found with ovarian autoimmune 
disease. Acanthosis nigricans reflects insulin resistance and androgen 
excess is seen with anovulation and menstrual dysfunction; the latter is 
noted with polycystic ovary syndrome (PCOS--see next section). 
Menstrual dysfunction can also be seen with pituitary adenomas. If 
growth hormone excess starts in childhood, an acromegalic tall stature 
results and later onset leads to acromegalic features of enlarged jaws and 
digits; acromegaly is typically seen with hyperprolactinemia. Rare tumors of 
the ovary or liver can produce human chorionic gonadotropin 
leading to menstrual dysfunction.  
POLYCYSTIC OVARY SYNDROME (PCOS) 
PCOS pathophysiology 
PCOS (PCO; hyperandrogenemia syndrome; old term: Stein-Leventhal 
syndrome) is a hyperestrogenic, hyperandrogenic state of anovulation 
found in 5%-10% of adolescent and adult females, representing 30% of 
adult women with chronic amenonorrhea and 75% with chronic 
oligomenorrhea       (see      table      22)     (1,6,83-87).         The        underlying 
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pathophysiology of PCOS is chronic dysfunction of hypothalamic 
stimulation of the pituitary, pituitary stimulation of the ovaries, and 
steroid feedback to the hypothalamus. There seems to be an increase 
GnRH that induces rhe pituitary to increase LH secretion (both basal  
levels and pulse amplitude), eithet as a cause or result of androgen 
synthesis from the ovaries. 
Hyperinsulinemia is part of PCOS and may also induce increased  
LH secretion (88). PCOS patients, whether obese or not, have increased 
levels of insulin in comparison to controls. The stale of insulin resistance 
found in PCOS patients leads to a state of byperinsulinism that induces 
increased androgens in hyperandrogenic females but not normal females. 
There is resistance to the normal hypoglycemic effect of insulin. This 
resistance is found in muscle and adipose tissue, but not in liver tissue. 
When puberty begins, the anterior pituitary reacts to increased 
estrogen levels by increasing LH levels and decreasing FSH production 
that lead to abnormal stimulation of ovarian-derived estradiol and 
androgens as well as abnormal maturation of ovarian follicles and a state 
of chronic anovulation. The anovulation leads to the prevention of 
cyclical progesterone secretion. Since there is less FSH secretion, antral 
follicular development is dysfunctional, oocyte degeneration increases, 
and ovulation does not occur. 
There is excess secretion of androgens that is mainly ovarian. In  
normal situations, progesterone is changed in the ovaries to 17-α-  
hydroxyprogesterone and chen to androstenedione in ovarian theca cells  
by 17-α-hydroxylase and 17,20-lyase. This androstenedione is converted  
to testosterone in theca cells and then estradiol in granulosa cells. In  
addition, PCOS patients have a congenital defect of cytochrome P450- 
l7-α-hydroxylase that leads to an increase in 17-α-hydroxylase and some 
increase in 17,20-lyase (desmolase) action causing an increase of 
testosterone concentration in the ovaries. Many PCOS patients also have 
decreased production and levels of sex steroid binding globulin (SSBG), 
thus allowing for higher free testosterone levels even if the total 
testosterone is normal. There is also heightened androgen production 
from the adrenal glands along with heightened peripheral production of 
estrone from aodrogens in adipose tissue, leading to increased stetoid 
levels in PCOS patients. Premature atresia of follicles and anovulation 
result from elevated testosterone levels.  The  elevated  estrone  levels 
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stimulate GnRH from the hypothalamus leading to increased LH levels and 
androgen secretion. Testosterone and androstenedione are 
metabolized to a potent androgen, DHT (5-α-dihydrotestosterone), in the 
skin. 
The result of PCOS pathophysiology is a chronic state of high 
androgen and estrogen levels, stimulating an increased but acyclical 
production of GnRH from the hypothalamus that causes a dysfunctional 
cycle of anovulation and hyperandrogenism. Such a PCOS 
pathophysiologic state can also occur because of an underlying state of 
elevated adrenal androgen production, as in Cushing's syndrome or 
congenital adrenal hyperplasia, some ovarian tumors or dysfunctional 
release of GnRH from the hypothalamus because of other conditions. 
Table 28. Laboratory test results in PCOS patients 
LH : Mild increase in levels 
FSH: Low limits of normal 
LH-f"SH ratio:> 2.5:1 
Estradiol: Moderate increase in levels 
17-hydroxyprogesterone: mild increase in levels 
Prolactin: Mild increase 
Androgen: mild to moderate increase in levels 
-free and total testosterone 
-dehydroepiandrosterone sulfate (DHEAS) (can be normal) 
-androstenedione 
-early morning urinary 17-ketosteroids
Sex hormone-binding globulin (SHBG): decreased 
Hyperinsulinemia (fasting levels of glucose/insulin ratio <4.5) 
Abnormal lipid profile 
-Increased cholesterol 
-Increased low-density lipoprotein 
-Increased very-low density lipoprotein 
-Reduced high-density lipoprotein 
-Increased triglycerides
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PCOS symptomatology 
Variable PCOS features (see table 28) may arise in females as or after 
puberty begins, including amenorrhea or irregular menstrual bleeding 
from anovulation, hirsutism, acne, and obesity. Hyperandrogenism is 
reflected by hirsutism (measured with the Ferriman-Gallway scale) in 
over 60%, acne vulgaris in 25%, and male-pattern alopecia in some 
PCOS patients (l,6,67 ,89,90). Virilization may occur as reflected in 
clitoromegaly (over 5 mm in diameter), voice deepening, and abnormal 
fat-muscle distribution. There may be premature adrenarche. At puberty, 
the patient may be overweight for height and even overtly obese. 
Acanthosis nigricans (velvety, hyperpigmented areas, especially in the 
axilla, neck and back) may reflect hyperinsulinemia, often associated 
with obesity (91). The family history may be positive for PCOS, diabetes 
mellitus, hyperinsulinism, hirsutism, infertility, and/or adrenal enzyme 
deficiency. 
The term, PCOS, represents a spectrum of hyperiosulinemia 
syndrome and an adolescent with PCOS may not have all the classic 
PCOS features found in adult females. Adolescents with PCOS may have 
one or two classic features along with suggestive laboratory findings (see 
next section) and later progress to other PCOS features. For example, 
there may not be oven obesity or enlarged ovaries until adulthood. 
Eventually the ovaries become enlarged with a thickened capsule that 
contains many small follicular cysts with tbeca intema hyperplasia 
("string of pearls") that is seen on an ultrasound examination. In adults 
obesity is noted in over 50% but ovulation may occur in 10% to 20% and 
as many as one-quarter may have regular menstrual cycles. Overt 
diabetes mellitus (type 2) may develop in some PCOS patients. 
PCOS laboratory studies 
Classic laboratory results in PCOS patients are listed in tables 22 and 28. 
The combination of an increased LH-FSH ratio (>2.5: 1) with increased 
free testosterone and androstenedione levels is suggestive of PCOS. A 
pelvic examination, pelvic ultrasound, or laparoscopy may identify 
polycystic and sometimes enlarged ovaries (bilateral); however, the 
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ultrasound in adolescents with PCOS may be non-specific and normal 
females may have the appearance of"polycystic" ovaries. 
The diagnosis of PCOS in young adolescents may be difficult and   
subtle based on general symptomatology along with an increase in 
androgens, estradiol (can be normal), a high LH-FSH ratio (>2.5: 1 ), with 
or without ultrasound confirmation of polycystic ovaries. A diagnosis of 
PCOS may be made if two of these three criteria are present: 
oligomenorrhea and/or anovulation, hyperandrogenism (clinical or 
biochemical evidence), and ultrasound evidence of polycystic ovaries 
(92). This is an expansion (Rotterdam criteria) of a National Institute of 
Health (NIH) conference in 1990 that defined PCOS as a disorder with 
hyperandrogenism and/or hyperandrogenemia, oligomenorrhea, and 
exclusion of known disorders (93). The exact definition with specific criteria 
remains controversial, especially for adolescents ( l ,93). 
If there is a rapid onset of hirsutism or virilization with high levels of 
testosterone (> 150-200 ng/dl), DHEAS (>700µ/dL) and  
androstenedione (>500 mg/dl), consider an adrenal tumor as the  
diagnosis. Polycystic ovaries can be seen with Cushing disease,  
congenital adrenal hyperplasia (including some partial enzyme  
deficiencies), hyperprolactinernia, and HAIR-AN syndrome. The HAIR- 
AN syndrome is a variant of PCOS with hirsutism, insulin resistance, 
acanthosis nigricans, and androgenization; these patients can also develop 
impaired glucose metabolism and hyperlipidemia (1,3,9,94). 
PCOS management  
Table 29  lists management options for adolescents with PCOS (95-100). 
If hirsutism is nor noted and the adolescent female is not sexually active 
needing contraception, 10 mg of medroxyprogesterone (Provera) can be 
prescribed for 12-14 days each month, to induce withdrawal bleeding. 
Oral contraceptives (estrogen-dominant) can also be used in combination 
with an antiandrogen medication (as spironolactone or cimetidine) to 
reduce clinical signs of androgen excess (as hirsutism or acne if present), 
and allow more clinically normal menstrual periods (1,6). The regular 
use of contraceptive steroids (pill or patch) provides management of the 
anovulation  and  unopposed  estrogen   stimulation  of  the  endometrium 
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found in patients with PCOS. Hormonal contraceptives can also suppress 
hyperandrogenism and increase the production of sex steroid binding 
globulin, thus helping prevent more hirsutism development.  
Table 29. Management options for PCOS patients 
Oral progesterone 
Oral contraceptives (also transdermal or  transvaginal hormonal 
contraceptives) 
Spironolactone (androgen receptor antagonist) 
Flutamide (androgen receptor antagonist) 
Metformin 
Electrolysis and thermolysis for hair removal 
Obesity management 
Acne vulgaris management 
Ovulation induction (not often used in adolescents) 
-Clomiphene citrate
-GnRH agonistic analogs (leuprolide acetate or nafarelin)
-Ovarian wedge resection. 
Laser "drilling" of the ovary (decrease ovarian stromal  steroids by 
reducing the amount of stroma) 
Management of additional endocrinopathies 
Hirsutism is also managed with androgen receptor antagonists as 
spironolactone (50-100 mg twice daily) or flutamide, another 
antiandrogen medication that inhibits androgen uptake (1,6,101-104). 
Other anti-androgen agents have been used, such as cyproterone acetate 
(Cyprostat). Metformin (Glucophage) reduces serum insulin levels, 
decreases ovarian cytochrome P450-17-α-hydroxylase activity, and 
improves hyperandrogenism in obese PCOS patients (98,99). Other 
medications used with type 2 diabetes mellitus have been used as well, 
including pioglitazone (Actos) and rosiglitazone (Avandia). Future 
sequelae of adolescent PCOS may include infertility, endometrial 
carcinoma, diabetes mellitus (type 2), hyperlipidemia, and cardiovascular 
disease (1,9). However, early intervention with alteration of dietary 
habits, physical exercise, and androgen suppression therapy can 
minimize adult morbidity.  Diet intervention is considered most  important 
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as fresh vegetables, fruit and high fiber nutrition can reduce weight, as 
well as metabolic consequences of PCOS. 
AMENORRHEA IN ADOLESCENT ATHLETES 
Irregular menstruation (i.e, amenorrhea and oligomenorrhea) is often 
seen in females with strenuous exercise patterns. involving 10%-15% of 
female athletes overall and two-thirds of the top female athletes (105- 
111).  Primary amenorrhea can also be seen as well, with a five month 
menarche delay noted for each year of strenuous exercise in the pre-
pubertal period (112). Secondary amenorrhea is well-known in females 
engaged in such sports as ballet, cycling, gymnastics, and distance 
running (108). Irregular menses is described in 12% of swimmers and 
cyclists, 20% of females involved in excessive exercise in general, 44% of 
ballet dancers, and 51& of endurance runners (108). 
As noted in table 25 there are many factors that influence menstrual 
cycles. Low body fat is not the only cause of menstrual irregularity and 
former statements that menses cannot occur below a body fat percentage 
of 17% have not been proven. A female athlete with amenorrhea can be 
at the same body fat level as one with regular menses (109). A major 
cause of lack of menstrual periods in athletes involved in excessive 
exercise patterns is the resultant hypothalamic amenorrhea or 
oligomenorrhea induced by dysfunction of GnRH productioi1 and LH 
pulsitivity (108). 
The strenuous exercise pattern of these athletes leads to a significant 
drain of energy that their relatively low caloric intake cannot correct, in 
order to sustain normal menses (109). Other factors may be involved as 
well. such as stress, positive family history of irregular menses, chronic 
illness, and others. A thorough search for other factors influencing 
menses is important, before concluding that the athlete's menstrual 
dysfunction is mainly due to intense exercise patterns. As noted before, 
the investigation should include congenital anomalies, short stature, 
hypoestrogenemia (see table 30), galactorrhea, virilization, and others 
(1,108-110,113). 
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Table 30. Methods to evaluate hypoestrogenemia in adolescents 
Physical and sex development (delay of sex development) 
Vaginal maturation index (VMI) 
Vaginal smear to evaluate for epithelial cell estrogenization 
Scrum estradiol level  
Body weight 
Bone mineral densitometry 
The combination of amenorrhea, dysfunctional eating patterns, and 
osteopenia or osteoporosis seen in some female athletes, has been termed 
the Female Athlete Triad by the American College of Sports Medicine 
(113). Various combinations of these three components can be seen in 
female athletes, especially those whose sport emphasizes a thin or even 
pre-pubertal physique that can be threatened by the normal changes of 
puberty. The need for thinness can lead to unhealthy intake of calories, 
protein, fat, and calcium. Young adolescents may develop delayed puberty 
with their continued prepubertal (hypoestrogenic) state, while 
postpubertal athletes can have chronic anovulatory amenorrhea and 
oligomenorrhea with hypoestrogenism (109,110). The low estrogen 
levels can prevent the development of normal peak bone mass with 
increased risks for os1eopenia, osteoporosis, and stress fractures. 
MANAGEMENT: FEMALE ATHLETE TRIAD 
Management of the adolescent female· athlete with amenorrhea or 
oligomenorrhea is based on the underlying etiology of the irregular 
menses. If strenuous physical activity is a paramount factor, reducing the 
exercise pattern by 10% or more and improving nutritional intake (with 
calcium supplementation) will be beneficial (108-111,114). The athlete 
can be educated that she is at increased risk for bone complications (i.e., 
reduced bone mineral density, osteopenia, and osteoporosis) if the 
menstrual problems are part of a state of chronic hypoestrogenemia 
(115). She may never develop a normal bone mineral density (BMD), if a 
state  of  chronic  amenorrhea  and  low  BMD occurs,  even  if  later  menses 
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becomes regular (108). Those with low BMD, and athletic occupations 
such as dancing. are at increased risk for stress fractures (108). 
Adolescents with the female athlete triad (i.e., menstrual dysfunction 
and/or abnormal eating patterns) should receive daily supplementation of 
calcium (1000-1500 mg per day), Vitamin D (400-800 IU), vitamin B 
complex. and viatamin E (100-200 IU) (108-111, 116). Research notes that 
about 50% of the required bone mass is obtained during adolescence, and 
it is recommended by many clinicians to provide estrogen 
supplementation in the form of oral contraceptives or conjugated 
estrogen for the purpose of seeking bone loss prevention (117, 118). The 
American Academy of Pediatrics recommends avoidance of hormonal 
management if she is within three years of menarche; however, oral 
contraception (or other estrogen supplementation) is suggested if she is 
three years after menarche and over 16 years of age while always seeking 
to improve nutritional intake, provide calcium supplementation, and 
recommend a reduction in exercise patterns (119).  
Unfortunately, many athletes who are committed to their sport will 
refuse to reduce exercise schedules or alter established dietary patterns 
(120). It is also important to understand that using estrogen 
supplementation is controversial and not proven to improve or even 
protect BMD with or without weight gain (108,109,121). It is also not 
possible to predict the outcome in a specific athlete with the female 
athlete triad, in terms of the actual effects of chronic menstrual 
dysfunction and potential hypoestrogenemia in a specific youth 
(108,120,122). Taking estrogen supplementation does not correct the 
underlying menstrual abnormality and once the estrogen is stopped, there 
is often a resumption of the previous menstrual dysfunction. Estrogen 
consumption can lead to a number of side effects, including nausea, 
emesis, breast tenderness, breast congestion, increased risk for clot 
potential, and others (52,62). Some research suggests that using oral 
contraceptives with ethinyl estradiol under 50 mcg may not prevent 
osteoporosis (123). In our clinics, however, we have an overall better 
outcome when these patients use combined oral contraceptives without 
placebo for an average of six months, compared to those who do not use 
OCPs (Omar, unpublished observation 2009). 
    Females with the most reduced BMD are those who are thin and 
inactive, though strenuous physical activity  patterns  that  involve  weight 
Menstrual Disorders in  Adolescent Females 379 
bearing can lead to high mechanical forces that neutralize the potential 
reduced BMD effect seen with a thin physique (108,120). Research 
showed that accretion of bone can be increased with weight-bearing 
exercise, and in some athletes with amenorrhea that results in having 
normal or even increased BMD; these athletes are gymnasts, runners, ice 
skaters, and tennis players (108,120).  
DYSMENORRHEA 
Primary dysmenorrhea 
General 
The term, primary dysmenorrhea, is used to define pelvic pain that 
occurs during menstruation in which there is no overt pelvic pathology; 
secondary dysmenorrhea refers to pain during menstruation due to 
specific pelvic abnormalities, such as endometriosis or pelvic 
inflammatory disease (see next section) (1,6,9,124,125). The pain of 
primary dysmenorrhea can be mild (does not affect normal activity and 
requires only minimal analgesic help), moderate (some reduction in 
regular activity and requires regular use of analgesics), and severe 
(unable to carry out regular activities and analgesics are typically not 
helpful). Severe pain is often associated with nausea and emesis. 
Primary dysmenorrhea typically begins 6 to 12 months after 
menarche, though it may not be noted until the third gynecologic year 
after menarche. The pain usually lasts 1-3 days typically initiating with 
the menstrual flow or up to several hours after menses begins; sometimes 
it occurs several to 48 hours before the menstrual flow starts. Nearly two-
thirds of ovulating females have some menstrual discomfort for 1-3 days 
of most ovulatory menses, with nearly half of them having mild pain, 
one-third having moderate pain, and 14% reporting severe pain. Primary 
dysmenorrhea is the most common medical cause of school or job 
absence and its incidence rises from the early teenage years through 
young adulthood and first pregnancy. 
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Etiology 
The pain of primary dysmenorrheal mensrrual cramps is due to the 
pathophysiology of the post-ovulatory period in which there is a  rise and 
fall of progesterone that leads to t he release of prostaglandins causing a n 
increase in uterine contractions and an irritation of endometrial nerve 
endings (1,6,9). The endometrium produces prostaglandins (e.g., PGF2α) 
and leukotrienes f rom arachidonic acid through cyclooxygcnase and 
lipooxygenase pathways, respectively. Reduced secretion of 
progesterone by the corpus luteum because of ovulation leads to a 
breakdown of lysosomes in endometrial cells, with a  release of 
phospholipase A2, which converts fatty acids (derived from cell 
membranes) into arachidonic acid. PGF2α and leukotrienes ( e.g., 
leukotricne B4 (LTB4) and leukotriene C4 [LTC4]) stimulate smooth 
muscle contractions.  
There is increased resting tone of the myometrium, heightened 
contractions (frequency and amplitude, and increased dysrhythmic 
contractions. Vasoconstriction induces ischemia of tissue as well as 
sensitization of myometrial neuronal endings co various pain-inducing 
chemicals. Those with primary dysmenorrhea have increased levels of 
circulating prostaglandins during menstruation (compared to those 
without such cramps). There may also be increased sensitivity to 
circulatory prostaglandins and increased levels of vasopressin that can 
lead to increased myometrial contractions and more pain. 
The reaction of individual adolescents to menstrual cramps can vary 
from some that are unable to continue regular activities, to others that 
seem Jess affected. Also, menstrual cramps can worsen with 
psychological factors, such as depression or anxiety. In addition, 
dysmenorrhea may be aggravated by factors such as longer menstrual 
flow, obesity, and the copper IUD. Decreased pain may be seen with 
parity, regular exercise, oral contraceptives, non-steroidal anti-
inflammatory drugs (NSAIDs), and the progesterone IUD (1). 
Symptomatology 
There may be a constant ache with superimposed crampy or spasmodic 
pain that is bilateral and symmetrical; the pain is localized to the lower 
abdomen but can radiate to the lower back or anterior thighs. A variety of 
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additional symptomatology may be seen, as noted in table 31. The 
differential diagnosis includes secondary dysmenorrhea and pain due to 
genitourinary tract infections (pelvic inflammatory disease), 
inflammatory bowel disease, endometriosis, tumors (ovarian or uterine), 
and pregnancy (particularly early spontaneous miscarriage). Figure 4 
provides a plan for the evaluation and treatment of dysmenorrhea. 
Table 31. Features associated with primary dysmenorrhea 
Backache 
Diarrhea 
Dizziness 
Fatigue 
Flushing 
General malaise 
Headache 
Inner thigh pain 
Lightheadedness 
Low abdominal pain 
Muscle cramps 
Nausea 
Vomiting 
Secondary dysmenorrhea. 
Though most episodes of dysmenorrhea in adolescents represent primary 
dysmenorrhea, secondary dysmenorrhea can also be seen. In this case, 
there is an underlying organic etiology to the pain. Clues to this diagnosis 
include that the pain begins at menarche or three or more years after 
menarche; also, there may be pain that is not colicky or crampy, it may 
be associated with dysfunctional uterine bleeding or changing menstrual 
patterns, it is not easily relieved with medications or there is a history of 
pelvic surgery. Table 32 lists causes of secondary dysmenorrhea that 
should be considered (1,6,9). Note that a diagnosis of a "retroverted" 
uterus is not a cause of secondary dysmenorrhea. 
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+ improvement ·
- lack of improvement
Used and adapted with permission: Blythe MJ. Common menstrual problems of 
adolescence. In: Braverman PK, Strasburger VC, eds. Office-based 
adolescent health care. Ado lesc Med 1997;8(1): 107, figure 2 and Greydanus 
DE, Patel DR, Pratt HD, eds Essential adolescent medicine. New York: 
McGraw-Hill, 2006:595. 
Figure 4. Evaluation and treatment for dysmenorrhea and endometriosis. 
History and Physical
Not sexually 
Active
Sexually active
Examine external genetalia
(Urine Culture)
Pelvic examination
(STD screen, urine culture)
Trial NSAIDs Consider OCs or patch & NSAIDs 
(Treat infection if present)
ImprovementPelvic US or pelvic exam
Trial of OCs or patch with NSAIDs for at least 6 months
Laparoscopy
Endometriosis
Other pelvic pathology
(see Table 1)
Normal pelvic
(Other organ system) Laser surgery
Consider GnRH agonists for 6 months
Consider acyclic, continuous monophasis OCs
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Table 32. Causes of secondary dysmenorrhea
Adhesions secondary to pelvic inflammatory disease or pelvic surgery 
Anatomical genital defects (obstructing mullerian defects) 
Complete cervical stenosis (with secondary amenorrhea and subsequent 
dysmenorrhea 
Endometriosis 
Inflammatory bowel disease 
Ovarian cysts 
Pelvic tumors (including uterine leiomyomata) 
Evaluation: Medical history 
A careful history is important in evaluating an adolescent who presents 
with what appears to be pelvic pain, seeking to distinguish primary from 
secondary dysmenorrhea or other non-gynecological causes. Table 33 
lists important points 10 consider in taking a medical history. Congenital 
malformations (i.e., vaginal septum and other Müllerian obstructive 
anomalies) may present with pain because of menstrual flow obstruction; 
there is a history of primary amenorrhea with normal breast 
development, cyclic dysmenorrhea, and/or hematocolpos. In this 
situation, the pain is typically present with menarche and imaging studies 
allow a precise diagnosis.  
Ovarian cysts may or may not be palpable and typically lead to 
lateralized adnexal tenderness. Fortunately, most ovarian cysts are 
asymptomatic, unlikely to cause pain, and finding a cyst does not 
necessarily implicate the cyst as causing the dysmenorrhea. Symptomatic 
cysts are typically follicular with such symptoms as irregular menses, 
urinary frequency, sensation of abdominal or pelvic heaviness, and 
constipation. Complications include cyst rupture with intra-abdominal 
bleeding and cyst torsion. Oral contraceptives may suppress the 
development of ovarian cysts. Fortunately, uterine tumors arc uncommon 
in adolescent females. 
Worsening menstrual pain in an adolescent who is sexually active 
may be caused by endometritis. The pain rs often worse during 
menstruation but occurs through the menstrual cycle. Pelvic 
inf1ammatory disease (PID)-induced menstrual pain may increase during 
the first seven days of the menstrual cycle and less frequently worsen in 
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the premenstrual period, with improvement described as the flow starts. 
Other evidence of PID will confirm the diagnosis, such as cervical 
motion tenderness, or uterine/adnexal tenderness and/or laboratory 
evidence of cervical infection with Neisseria gonorrhoeae or Chlamydia 
trachomatis (1,6,9,126). 
Table 33. Medical history in a patient with dysmenorrhea 
Age at menarche 
Last time menstruation was regular (if at all) 
Pain description: location, timing to menarche, menstrual flow, frequency 
Severity of the pain: mild, moderate, severe (are activities disrupted?) 
Do pain medications improve or relieve the pain? 
Flow description (duration and quantity) 
Association with systemic factors (Table 31) 
Sexual history and use of any contraception 
History of pregnancy (and its outcome) 
History of sexually transmitted diseases 
History of dyspareunia 
History of other systemic disorders (i.e., gastrointestinal, genitourinary, 
others) 
History of surgical procedures 
Family history of various gynecologic conditions (Table 32) 
(dysmenorrhea, endometriosis, ovarian cysts, infertility, virilization, 
cancer, others) 
Pain associated with vaginal bleeding may be due to early pregnancy 
complications, such as ectopic pregnancy or miscarriage. Painful vaginal 
bleeding can also be due co gastrointestinal disorders, urologic disorders, 
intra-abdominal abscess., lesions of the sacrum. and orthopedic infections 
(involving the hips and other joints). These conditions cause acute or 
recurrent lower abdominal or pelvic pain but not the cyclical pain of primary 
dysmenorrhea.  
Evaluation: Physical examination and  laboratory testing 
If the  history  suggests  mild  primary  dysmenorrhea  with  no  pain  apart 
from  the menstrual  periods  in an adolescent who is not sexually active,  a 
pelvic examination  is  not necessary.  A  general  examination can be done 
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that includes an inspection of the external genitalia to rule out an 
imperforate hymen. If she is sexually active or if the pain is or becomes 
moderate or severe. a pelvic examination should be part of the physical 
examination process. 
Laboratory testing and imaging is not usually needed for those with 
what appears to be mild to moderate primary dysmenorrhea that responds 
to basic medical management (see next section). If she is sexually active, 
the possibility of a sexually transmitted disease and pregnancy should be 
ruled out. The history and general physical examination may point to a 
non-gynecologic cause, such as gastrointestinal, urinary, others; in such 
cases, appropriate testing should be done (i.e., complete blood count, 
urinalysis, urine culture, stool for occult blood, others as appropriate). 
Ultrasonography is useful to identify such conditions as a pelvic 
mass, pelvic abscess, adnexal torsion, ovarian cysts, pregnancy, and 
others. The pelvic CT can be helpful if the ultrasound is indeterminate, 
while the pelvic MRI is more sensitive to identify Müllerian anomalies. 
Laparoscopy is needed to identify endometriosis or pelvic adhesions. 
PRIMARY DYSMENORRHEA MANAGEMENT: NSAIDS 
The first line of medical treatment for primary dysmenorrhea is one of 
the NSAIDs (nonsteroidal anti-inflammacory drugs). NSAIDs include 
type I inhibitors (carboxylic acids) (sec table 34) and type II (enolic acids 
that include pyrazolones [phenylbutazone] and oxicams [piroxicam]) 
(1,6,9,125). Enolic acids inhibit cyclic endoperoxidc cleavage enzymes 
(reductase isomerase) after formation of cyclic endoperoxides as a later 
step in prostaglandin production. Enolic acid medications are not as 
effective as carboxylic acids (see table 33) ant have more side effects. 
Thus, type I inhibitors (carboxyJic acids) are the main type of NSAIDs 
used to manage primary dysmenorrhea. 
Carboxylic acids suppress cyclic cndope1oxide synthetase at the 
cyclooxygenase level and are effective medications to relieve the pain of 
primary dysmenorrhea. However, aspirin has limited anti-inflammatory 
effect on the endometrium and is not a potent reliever of menstrual 
cramps. Indomethacin is more effective, but its many side effects limits 
its use   for treatment of primary dysmenorrhea; these adverse ef fects 
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include gastrointestinal effects (i.e., ulceration, perforation, bleeding). renal 
insufficiency, breast tenderness, headaches, vaginal bleeding, and others.  
Table 34. NSAIDs: Type 1 inhibitors: Carboxylic adds 
1. Salicylic acid esters: aspirin
2. Acetic acids: indomethacin
3. Propionic acids: ibuprofen, naproxen, naproxen sodium, and 
ketoprofen
4. Fenamic acids: mefenamic acid, meclofenamate
Thus, propionic acids (i.e., ibuprofen, naproxen sodium, others) have 
been used because of effective relief of pain with less toxicity than the 
other mentioned medications; they are FDA-approved for treatment of 
primary dysmenorrhea. Side effects include gastrointestinal effects and 
headaches. Propionic acids (see table 34) are available as over-the-  
counter medications. Naproxen sodium bas a long half-life allowing a 
twice-a-day dosing. Ketoprofen inhibits prostaglandin and leukotriene 
synthesis, stabilizes lysosomal membranes, and has anti-bradykinin  
action. Dosages for propionic acids are noted in table 35. Fenamic acids 
have a rapid onset of action, block myometrial receptor sites for 
prostaglandins that have been synthesized, inhibit 5-lipooxygenase  
activity (that can suppress production of leukotrienes), and can reduce 
heavy flow of menses. Table 35 lists basic dosage of mefenamic acid.  
An NSAID (as ibuprofen, naproxen sodium, naproxen, others) is 
started at the onset of the menstrual flow or even before the anticipated 
flow onset, especially if pain precedes the bleeding. Sta,ting the medication 
before the flow starts is also helpful if emesis is part of the  
menstrual cycle. The medication is continued for 2-4 days, depending on 
how long the pain usually lasts. Improvement of the pain and even the 
amount of blood loss is noted (see section on DUB). If a propionic acid is 
not beneficial after a few months trial. the adolescent female can try a 
fenamic acid for a few more months' trial. Overall efficacy in partial or  
full relief of pain is as high as 80%. Failure of improvement may be due  
to  the   lack  of  prostaglandin   synthetase   inhibitors   blocking   the   5-
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lipooxygenase pathway that allows continued production of leukotrienes 
and continued dysmenorrhea. 
Table 35. NSAIDs for the treatment of primary dysmenorrhea 
Drug Initial Dose Maintenance Maximum 
(mg) Dose Dose/24 hours 
(mg) 
Ibuprofena 400 400 mg q4h 3200 
Ketoprofena 25-50 25-50 mg q6-8h 300
550
500 
500 
275 mg q6-8h or  
550 mg q12h   
250 mg q6-8h 
250 mg q6h 
1250 
Not established 
Naproxena 
sodium 
Naproxen 
Mefenamic acid 
a Available as over-the-counter drugs (ibuprofen; 200 mg tablets; ketoprofen: 
12.5 mg tablets; naproxen sodium: 220 mg tablets). 
PRIMARY DYSMENORRHEA MANAGEMENT:
ORAL CONTRACEPTIVES
Oral contraceptives are also used for primary dysmenorrhea if NSAIDs 
are not effective and may be the first line of treatment for sexually active 
youth with dysmenorrhea (1,6,9,125). Oral contraceptives prevent 
ovulation that in turn prevents the post-ovulatory high prostaglandin 
levels due to a corpus luteum. The lack of such high progesterone levels 
prevent an important step in prostaglandin production and thus, lack of 
overt painful menstrual cramps. Added benefits include effective 
contraception and less menstrual flow (see DUB section). An efficacy 
rate of 90 to 95% can be seen with the use of oral contraceptives in the 
management of primary dysmenorrhea. Similar results can be achieved 
with use of other hormonal contraceptives such as: transdermal, 
transvaginal, injectible, or implantable (subdermal) methods. A 
combination of hormonal contraceptives and NSAIDs can also be 
effective.  If  the use of NSAIDs and/or oral contraceptives  is  not 
1375 
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effective, the possibility of secondary dysmenorrhea should be re-
considered. 
PRIMARY DYSMENORRHEA MANAGEMENT: OTHERS
A variety of other measures may be useful in managing primary 
dysmenorrhea, including use of a menstrual calendar to get a clear 
picture of menstrual timing, reduction of sugar as well as caffeine, 
encouragement of adequate rest as well as regular exercise, and reduction 
of excess stress ( 1,6,9). Psychological factors (as depression and anxiety) 
can worsen pain from various causes. Fish consumption containing 
omega-6 fatty acids (e.g., salmon) can help minimize menstrual cramps. 
Unproven options with anecdotal testimonies of success in some adult 
patients include calcium channel blockers (i.e., nifedipine), acupuncture, 
and cranscutaneous electrical nerve stimulation (TENS). Side effects of 
nifedipine include headaches and hypotension. Education of the 
adolescent female about dysmenorrhea and its treatment options is 
important (127). 
Table 36. Premenstrual syndrome ( PMS) symptomatology 
Emotional Features
Anecdotal reports of violence and suicide   
Anger 
Anxiety 
Concentration difficulties 
Crying 
Decreased libido 
Depression 
Feelings of  being out of control or overwhelmed 
Lethargy 
Mood swings 
Withdrawal from usual activities 
Physical Features 
Acne 
Anorexia 
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Bloating 
Breast tenderness or swelling 
Constipation 
Diarrhea  
Edema 
Facial puffiness 
Fatigue 
Headache 
Increased appetite 
Lower abdominal or pelvic pain 
Pain: joints or muscles 
Swelling of hand  
Swelling of feet 
Weight gain 
PREMENSTRUAL SYNDROME
Premenstrual syndrome (PMS) refers to a variety of symptoms that begin 
during the last part of the luteal menstrual cycle, just prior to the 
menstrual flow, and resolve with the onset of menstruation so that they are 
absent the week after menses starts (1,6,9,128,129). PMS may begin 
several days to two weeks prior to menses and the symptoms can be 
divided into emotional and physical features (see table 36); patients 
report various combinations of these features. Most females of 
reproductive age will note some PMS symptoms, while 3% to 8% report 
severe enough emotional features (i.e, depression, anxiety, inability to 
perform daily tasks) that the condition meets criteria for Premenstrual 
Dysphoric Disorder (PMDD) as defined by the American Psychiatric 
Association's (APA) Diagnostic and Statistical. Manual of Mental 
Disorders (1994, 2000) (130-132). Patients with PMDD have five or 
more of these APA criteria (i.e., sadness, loss of self-worth, mood 
lability, anxiety, withdrawal from social relationships, anger, persistent 
irritability, others) in the luteal menstrual phase for at least one year. 
PMS should be identified as a separate category from dysmenorrhea. 
Pelvic pain is not a symptom of PMS, unless other disorders are present, 
such as endometriosis.  PMS may be confused with  other disorders 
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including hypothyroidism, chronic fatigue syndrome, collagen vascular 
disorder, anemia, diabetes mellitus, and others (1,6,9). A number of 
conditions can be worsened by menstruation and can add to the 
differential diagnostic confusion (see table 37). 
Table 37. Conditions worsened by menstruation 
Acute intermittent porphyria 
Erythema multiforme 
Migraine headaches 
Periodic fever  
Periodic hypersomnia 
Periodic paralysis 
Recurrent anaphylaxis 
Rheumatoid arthritis 
PMS etiology 
Though the precise etiology is not known, etiologic theories often center 
on dysfunction of serotonin or γ -aminobutyric acid A (GABA-A)  
(1,6,9). For example, one theory implicates heightened sensitivity to 
hydroxy-tryptamine (5-HT) receptors with reduced levels and impaired 
uptake of serotonin. Some research has concluded that anxiety can be 
enchanced by dysfunctional interaction of metabolites of progesterone and 
receptors of γ-aminobutyric acid A (GABA-A) receptors. Other  
research notes that increasing late luteal phase levels of PCO2 can induce 
reduced threshold for a panic attack, Recurrent episodes of PMS may lead 
to increased sensitization to these mechanisms and more PMS 
symptomatology. Current research implicates a corn pl ex interaction 
between prostaglandins, central neurotransmitters (as serotonin), 
endogenous opioid peptides, peripheral autonomic nervous system, and 
ovarian steroids. Psychological issues may be worsened by PMS  
symptoms but are not primarily causative of PMS. 
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PMS management 
General measures often recommended for youth with PMS include 
adequate re-st. exercise. regular hot baths, reduced intake of caffeine as 
well as sugar, reduced salt intake, avoidance of alcohol, and reduction in 
factors causing excessive stress (1,6,9). If depression or anxiety is noted, 
psychological management may be helpful (133). Beneficial effects on 
the emotional features of PMS bas been seen by using selective serotonin 
reuptake inhibitors (SSRIs) such as fluoxetine (20 mg daily), sertraline 
(50 mg daily), or paroxetine (20 mg daily) (1,6,9,128,134,135). The 
United Stares FDA has placed a "black box" warning on SSRis due to 
increased suicidal ideation and behavior noted in children and 
adolescents taking SSRIs (136). Patients with anxiety may benefit from 
the use of anxiolytics (alprazolam or buspirone). Tricyclic 
antidepressants have been helpful as well, including clomipramine (136). 
Though not recommended for adolescents, adult females with severe 
PMS have reported improvement with gonadotropin-releasing hormone 
(GnRH) agonists (such as leuprolide [Lupron] and buserelin (Suprefact]) 
that induce a medical oophorectomy by suppressing gonadotropin release 
with resultant suppression of ovulation and ovarian hormone synthesis. 
NSAIDs (such as ibuprofen) may be helpful probably by improving 
breast and/or pelvic pain. Diuretics (such as hydrochlorothiazide or 
spironolactone) may be beneficial in some by improving PMS edema or 
weight gain; however, abuse of diuretics may lead to increased edema. 
Bromocriptine is a dopamine-receptor agonist that has been used in adult 
females to relieve severe mastalgia seen in some with PMS. Measures 
attempted, but without specific research to verify benefit, include oral 
contraceptives. progesterone. thyroid hormone supplementation, lithium, 
evening primrose oil, atenolol, prostaglandin inhibitors, vitamin E or B6 
supplementation, and supplementation with calcium or magnesium 
(1,6,9,137).  
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PELVIC PAIN 
Mittelschmerz 
This refers to pain in the lower abdominal quadrants that occurs in the 
middle of the menstrual cycle in association with ovulation (1,9,138). 
The cause of the pain is probably the result of pelvic irritation induced by 
contents of the discharged (dominant) ovarian follicle. Mittelschmerz 
(German: middle pain) does not occur in anovulation. The pain or 
discomfort is usually unilateral, crampy, lateralized, lasts from several 
hours to four days, and typically changes sides from month to month. It 
may be accompanied by mild bleeding or vaginal secretion changes. 
Fortunately Mittelschmerz is rarely severe and sometimes can be 
confused with an ovarian cyst, ovarian torsion, ectopic pregnancy or 
appendicitis. Management includes education of its cause, reassurance, 
analgesics, and if severe, ovulation inhibition with oral contraceptives. 
Endometriosis 
Endometriosis involves the development of functional endometrial tissue 
(i.e., stroma and glands) outside the uterus (1,6,139-141). Though it 
mainly presents in adult females in the third and fourth decade of life, 
it may be seen in adolescent females as well; it has been reported as young 
as 101/2 years of age. Incidence of 10%-17% has been reported in adult 
females and 40%-65% or more of adolescents with chronic pelvic pain 
(including secondary dysmenorrhea) may have endometriosis as noted on 
laparoscopy (1,140-142). 
Etiology 
Endometrial tissue can be refluxed from the oviducts during 
menstruation in a condition termed retrograde menstruation or 
endometrial tissue may develop from many small cysts found on various 
structures: ovaries, surface of the uterus, pelvic ligaments or the 
peritoneum (coelomic metaplasia). Etiologic theories include genetic 
factors,  lymphatic-vascular  metastases,  and  immunologic  deficiencies  in 
Menstrual Disorders in Adolescent Females 393 
which cell-mediated defects lead to endometrial cells that are not cleared 
from non-uterine structures (1,139-143). Endometriosis can be found in 
7% of close relatives of a patient with this condition, in contrast to 1% of 
controls (1). The pain of endomeniosis develops when endometrial cysts 
enlarge or swell during the menstrual cycle; pain can also occur because 
of pelvic adhesions or because nerve endings are stimulated. 
Symptomatology 
Classic features of endometriosis incude severe dysmenorrhea, pelvic 
mass, and infertility (140-143). Symptoms can be similar in adolescents 
versus adult females, though adolescents are more likely to have 
congenital reproductive tract anomalies (such as imperforate hymen, 
transve.rse vaginal septum, uterine anomalies, hematometra, 
hematocolpos) and renal agenesis (144). The dysmenorrhea may be 
localized to the lower abdomen, groin, thigh, back, or deep in the pelvic. 
The pain can be worsened by coitus, improved with rest, and may 
become cyclical, acyclical, aud chronic. There is no correlation between 
the intensity of tbe pain and the extent of endoroetriosis (i.e., the number 
of endometriotic lesions does not correlate with the severity of the pain). 
There may be abnormal menstrnal bleeding (including bleeding 
before menses), dysuria, clinical hematuria, suprapubic pain, and 
dyspareunia. There may be primary amenorrhea with normal sexual 
development; in otl1ers there is dysfunctional uterine bleeding or 
persistent pain worse.ning with meostTuation. Bowel symptomatology 
may occur especially in the late luteal and menstrual phases; these 
symptoms include rectal pressure, urgency, and pain with defecation 
(dyschezia). The symptoms can be modified by complica1ions including 
adhesions, mass effects, internal bleeding, or even changes in bowel or 
bladder functions. Endometriosis can present as an adnexal mass, large 
ovarian endometriornas, or with diffuse disease.   
Diagnosis 
The correct diagnosis of endometriosis begins with a careful history as 
reviewed under Symptomatology above. The pelvic eitaminatiou may be 
normal or, especially if performed during the late Juteal phase of the 
menstrual cycle, may reveal pelvic tenderness, thick broad ligaments, 
immobile  (fixed) uterus, or  variable nodularity with or without 
394 Donald E. Greydanus, Hatim A. Omar, Artemis K. Tsitsika et al. 
tenderness (see table 38). Ultrasonography may reveal various cysts 
scattered in the pelvis or may reveal an adnexal mass, while a pelvic 
l'\IIRI is the best procedure to identify genital reproductive tract anomalies 
and a hysterosalpingography can be useful as well. CA-125 (cell surface 
antigen) can be increased in patients with endometriosis and though 
it has a low sensitivity (i.e., is not a good screening test), serum levels of 
CA-125 have been used to follow patient response to management (1). 
Laparoscopy with biopsy is the confirmatory test for endometriosis 
and is recommended for females with chronic pelvic pain of unknown 
cause that does not improve with NSAIDs and oral contraceptives 
(1,6,140-146). Endometrial lesions in youth may have a different 
appearance than in adult females and the examiner must be familiar with 
lesions found in adolescents (140,143). Early lesions of endometriosis 
are pigmented, pale, cystic, vesicular, or hemorrhagic; more typical adult 
lesions reveal areas characterized with retraction, fibrosis, "powder burn" 
lesions or overt endometriomas that can be very small or several 
centimeters in diameter.  
DIFFERENTIAL DIAGNOSIS OF CHRONIC PEL VIC PAIN 
Tables 22, 38-40 list causes of acute and chronic pelvic pain in 
adolescent and adult females (147,148). Consultation is often necessary 
with experts in gynecology, surgery, urology, and others (1,6,9,147,148). 
A thorough history and physical examination is important to identify the 
specific cause along with various laboratory testing that includes 
complete blood count, urinalysis (with urine culture), pregnancy testing, 
and STD te-sting (Chlamydia trachomatis, Neisseria gonorrhoeae, others) 
(126,149). Pelvic ultrasonography and diagnostic laparoscopy are often 
important aids in identifying a specific etiology. Laparoscopic results in 
patients with acute pelvic pain include a normal pelvis in 30%. ovarian 
cysts in 40%, pelvic inflammatory disease in 30%, appendicitis in 10%, 
adnexal torsion in 5%, ectopic pregnancy in 3% (150). Laparoscopic 
findings in patients with chronic pelvic pain of 3 months duration or 
more include endometriosis in 45%, a normal pelvis in up to 40%, pelvic 
inflammatory disease in up to 15%, postoperative adhesions in up to 
13%, uterine anomalies in 5% to 8%, and ovarian cysts in 5% (150). 
Table 38. Differential diagnosis approach to pelvic pain*
Characteristics of pain 
MIDLINE LOCATION 
Cyclical, normal bleeding 
Acute, irregular bleeding 
Unrelated to menses, urinary 
symptoms*
LATERAL LOCATION 
Cyclical, normal bleeding 
Acute, postmenstrual 
Likely diagnosis 
Primary dysmenorrhea 
Endometriosis 
Endometritis 
Threatened or septic abortion 
Cystitis 
Normal uterine pregnancy 
Mittelschmerz 
Endometriosis 
Salpingitis or pelvic inflammatory 
disease 
Confirmatory investigations 
History; pelvic examination (normal) 
Pelvic examination; sonography; 
laparoscopy 
Pelvic examination, cultures; CBC; 
sedimentation rate 
History; pelvic examination; 
pregnancy rest 
History; urinalysis, urine culture 
History; pregnancy test 
History (timing, nature); pelvic 
examination (normal) 
Pelvic examination; sonography; 
laparoscopy 
Histocy; pelvic examination., cultures; 
CBC, sed rate; laparoscopy 
History; pelvic examination, 
pregnancy test 
Ectopic pregnancy 
Apendicitis 
.Acute abnormal bleeding 
Unrelated to menses, acute 
Unrelated to menses. chronic Constipation 
Pelvic osteomyelitis 
History; physical examination; CBC: 
radiography 
History; urinalysis; radiography 
History: rectal examination 
Physical examination; radiography: 
gallium scan 
History; exclusion of others; 
psychosocial evaluation 
Psychogenic 
Abbreviation: CBC= complete blood count. 
aDysuria and urinary frequency may be associated with infection, pregnancy, and psychogenic factors. 
Reprinted, with permission, from: Greydanus DE. Breast and gynecological disorders. In: Hofmtum AD. Greydanus DE, eds. 
Adolescent medicine, 3rd ed. Stamford, CT: Appleton I.ange, 1997:547. 
Ureteral colic
·Table 39. Causes of chronic pelvic pain in women
• CYCLICAL 
Atypical cyclical 
Endometriosis 
Adenomyosis 
Ovarian remnant syndrome 
Chronic functional cyst formation 
•  GASTROINTESTINAL 
Irritable bowel syndrome 
Ulcerative colitis 
Granulolmatous colitis (Crohn's 
disease) 
Carcinoma
Infectious diarrhea 
Recurrent partial small bowel 
• GYNECOLOOICAL 
Noncyclical 
Adhesions 
Endomettiosis 
Salpingo-oophoritis 
Acute 
Subacute 
Ovarian remnant syndrome 
Pelvic congestion syndrome 
Ovarian neoplasms 
Pelvic relaxation 
•  CYCLICAL 
Primary dysmenorrhea 
Secondaiy dysmenorrhea 
Imperforate hymen obstruction 
Diverticulitis 
Hernia 
Abdominal angina 
Recurrent appendiceal colic 
·
Transverse vaginal septum 
Cervical stenosis 
Uterine anomalies 
(congenital malformation, bicornuate 
uterus, blind uterine horn)
Intrauterine synechiae (Asherman's •  GENITOURINARY
• NEUROLOGICAL 
Nerve entrapment syndrome 
Neuroma 
• MUSCULOSKELETAL
Low back pain syndrome 
Congenital anomalies 
Scoliosis and kyphosis 
Spondylolysis 
Spinal injuries 
Inflammation 
Tumors 
Osteoporosis 
Degenerative changes 
Coccydynia 
Myofascial syndrome 
• SYSTEMIC 
Acute intermittent porphyria 
Abdominal migraine 
Systemic lupus erythematosus 
Lymphoma 
Neurofibromatosis 
syndrome) 
Endometrial polyps 
Uterine leiomyoma 
Adenomyosis 
Pelvic congestion syndrome 
Endometriosis  
Recurrent or relapsing 
cystourethritis 
Urethral syndrome 
Interstitial cystitis 
Ureteral diverticuli or polyps 
Carcinoma of the bladder 
Ureteral obstruction
Pelvic Kidney 
Source: Reprinted with permission, from Rapkin AJ, Reading AE: Chronic pelvic pain. Curr Probl Obstet Gynecol Fertil 199;
 14:101. 
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Management 
Table 41 and figure 4 list treatment options for endometriosis which is a 
chronic condition of variable severity that requires consultation wich 
gynecologic consultants (151). NSAIDs are not usually helpful in 
relieving the pain of endometrosis. Reduction and even disappearance of 
endometrial tissue outside of the uterus may occur with the use of oral 
contraceptives (OCPs), transdermal or transvaginal hormonal 
contraceptives or medroxyprogesterone acetate (Provera [30-50 mg 
orally once a day] or Depo-Provera [150 mg intramuscularly once a 
month or every 3 months]) (1,6.143). Side effects of progestins include 
weight gain, irregular bleeding, depression, bloating, and others. A 
progestin-dominant oral contraceptive may be helpful in some. 
Another treatment option is methyltestosterone (5-10mg bucally 
each day) since androgens inhibit endometrial growth. Side effects of 
androgens include virilization of the female and teratogenic potential 
( masculinization of a female fetus). Gonadotropin-releasing hormone 
agonises (leuprolide acetate or nafarelin acetate) are also used alone or in 
combination with estrogen because these agonists induce a state of 
menopause that is reversible leading to absence of menses, vaginal 
dryness, hot flashes, and bone loss. These agonises are typically 
withdrawn after 6 months, though adding estrogen may allow longer 
agonise use. Danocrine (Danazol) is a l 7a-ethinyl-testosterone derivative 
and is also used; it is prescribed at 400 mg twice a day orally, leading to 
improvement of pain in 90% (143). Adverse effects include weight gain, 
edema, abnormal liver function tests, fetal androgenization, acne, lipid 
dysfunction, and ochers. Anastrozole is a drug (aromatase inhibitor) used 
to treat breast cancer that has been used in adult women with 
endometriosis along with oral contraceptives to treat endometriosis 
(152). 
Table 40. Differential diagnosis of pelvic masses 
Characteiistic of Mass Differential Diagnosis Confirmatory History, 
Findings, and Procedure 
MIDLINE LOCATION Pregnancy 
With amenorrhea or abnormal 
menses Hematocolpos, hematometra 
Uterine sarcoma (rare) 
With normal menses Bladder 
Functioning ovarian cyst 
LATERAL LOCATION With 
amenorrhea or abnormal 
menses Ovarian tumor 
Polycystic ovary syndrome 
History of sexual activity; positive pelvic 
examination 
History of no menses, cyclic pelvic pain; perineal 
examination reveals imperforate hymen, vaginal 
stenos is 
Negative pregnancy test; uterine enlargement; 
sonography CT; tissue diagnosis 
History of acute retention; findings of herpetic or 
other lesions precipitating retention; catheterization 
History of menstrual irregularity; negative 
pregnancy test; unilateral mass; physical or 
laboratory evidence of hormonal abnormalities; 
sonography, laparoscopy, tissue diagnosis 
As above with bilateral ovarian enlargement 
History of sexual activity; pregnancy test may or 
may not be positive; sonography; may or may not 
Ectopic pregnancy 
With normal menses Tuboovarian abscess 
Nonfunctioning ovarian cyst 
Appendiceal abscess 
have pain or tenderness; may present as acute 
emergency 
History and findings compatible with pelvic 
inflammatory disease; sonography, laparoscopy 
History of pain or asymptomatic; unilateral mass; may 
be very large; sonography, laparoscopy, tissue 
diagnosis 
History of appendicitis (or acute abdominal 
condition); positive rectal or abdominal 
examination; may be difficult to distinguish from 
pelvic inflammatory disease; sonography, 
laparotomy 
History of constipation; positive rectal or 
abdominal examination; abdominal 
roentgenograms 
Fecal impaction 
Abbreviation: C T =  computed tomography 
Reprinted, with permission, from: Gre,danus DE: Breast and gynecological disorders. In: Hofmann AD, Greydanus DE, eds. 
Adolescent medicine, 3rd ed. Stamford, CT: Appleton Lange, 1997:559. 
Surgical management options are noted in table 41 
(1,6,140,141,143,145,150-155). Hormonal treatment can be provided 
after surgery because endometriosis often continue  after surgical 
treatment. Correction of congenital anomalies that may be present is also 
important, as for example correction of an imperforate hymen, a 
transverse vaginal septum or excision of a rudimentary blind horn. 
Surgery should seek to preserve fertility if possible. 
Table 41. Treatment options for endometriosis 
Oral contraceptives 
Medroxyprogesterone acetate (Provera or Decpo-Provcra) 
Androgens (methyltestosterone) 
Gonadotropin-releasing hormone agonists (leuprolide acelate or nafarelin 
acetate) 
Danazol (danocrine) 
Anastrozole (Arimidex) 
Laparoscopic ablation 
LUNA (Lase, Uterosacral Nerve Ablation) 
Electrocautcry 
Thermocoagulalion 
Laparotomy with resection of endometriomas 
Presacral neurectomy 
Correction of associated congenital reproductive anomalies 
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